Therapeutic	O
concentrations	O
of	O
glucocorticoids	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
without	O
impairing	O
their	O
responsiveness	O
to	O
gamma	B-protein
interferon	I-protein
.	O

By	O
exposing	O
human	B-cell_type
blood-derived	I-cell_type
macrophages	I-cell_type
and	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
in	O
vitro	O
to	O
dexamethasone	O
,	O
we	O
showed	O
in	O
these	O
studies	O
that	O
glucocorticoids	O
markedly	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
macrophages	B-cell_type
but	O
not	O
macrophage	B-cell_type
activation	O
by	O
lymphokines	B-cell_type
.	O

As	O
little	O
as	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
mol/liter	O
of	O
dexamethasone	O
prevented	O
macrophages	B-cell_type
from	O
inhibiting	O
germination	O
of	O
Aspergillus	O
spores	O
or	O
from	O
eliminating	O
ingested	O
bacteria	O
such	O
as	O
Listeria	O
,	O
Nocardia	O
,	O
or	O
Salmonella	O
.	O

Damage	O
to	O
macrophage	B-cell_type
function	O
was	O
inhibited	O
by	O
progesterone	O
and	O
appeared	O
to	O
be	O
receptor-mediated	O
.	O

In	O
accordance	O
with	O
in	O
vivo	O
observations	O
,	O
dexamethasone	O
required	O
24-36	O
h	O
to	O
suppress	O
antimicrobial	O
activity	O
.	O

While	O
glucocorticoids	O
interfered	O
with	O
base-line	O
activity	O
of	O
macrophages	B-cell_type
,	O
dexamethasone	O
concentrations	O
comparable	O
to	O
drug	O
levels	O
in	O
patients	O
had	O
no	O
effect	O
on	O
macrophage	B-cell_type
activation	O
.	O

Proliferating	O
lymphocytes	B-cell_type
and	O
gamma-interferon	B-protein
thus	O
increased	O
the	O
antimicrobial	O
activity	O
of	O
phagocytes	B-cell_type
exposed	O
to	O
glucocorticoids	O
over	O
that	O
of	O
control	O
cells	O
.	O

Macrophage	O
activation	O
and	O
correction	O
of	O
the	O
dexamethasone	O
effect	O
by	O
gamma-interferon	B-protein
,	O
however	O
,	O
was	O
dependent	O
on	O
the	O
pathogen	O
.	O

The	O
lymphokine	B-protein
enhanced	O
the	O
antimicrobial	O
activity	O
of	O
dexamethasone-treated	B-cell_line
macrophages	I-cell_line
against	O
Listeria	O
and	O
Salmonella	O
but	O
not	O
against	O
Aspergillus	O
or	O
Nocardia	O
.	O

Dexamethasone-induced	O
damage	O
to	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
in	O
vitro	O
parallels	O
observations	O
that	O
glucocorticoids	O
render	O
laboratory	O
animals	O
susceptible	O
to	O
listeriosis	O
and	O
aspergillosis	O
by	O
damaging	O
resident	O
macrophages	B-cell_line
.	O

Suppression	O
of	O
macrophage	B-cell_type
antimicrobial	O
activity	O
should	O
thus	O
be	O
considered	O
when	O
treating	O
patients	O
with	O
glucocorticoids	O
;	O
its	O
prevention	O
by	O
gamma-interferon	B-protein
might	O
be	O
beneficial	O
for	O
some	O
but	O
not	O
all	O
pathogens	O
.	O

Therapeutic	NULL
Concentrations	NULL
of	NULL
Glucocorticoids	NULL
Suppress	NULL
the	NULL
Antimicrobial	NULL
Activity	NULL
of	NULL
Human	NULL
Macrophages	NULL
without	NULL
Impairing	NULL
Their	NULL
Responsiveness	NULL
to	NULL
Gamma	NULL
Interferon	NULL
Andreas	NULL
Schaffner	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Ziirich	NULL
,	NULL
CH-8091	NULL
Ziirich	NULL
,	NULL
Switzerland	NULL
Abstract	NULL
By	NULL
exposing	NULL
human	NULL
blood-derived	NULL
macrophages	NULL
and	NULL
alveolar	NULL
macrophages	NULL
in	NULL
vitro	NULL
to	NULL
dexamethasone	NULL
,	NULL
we	NULL
showed	NULL
in	NULL
these	NULL
studies	NULL
that	NULL
glucocorticoids	NULL
markedly	NULL
suppress	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
but	NULL
not	NULL
macrophage	NULL
activation	NULL
by	NULL
lymphokines	NULL
.	NULL

As	NULL
little	NULL
as	NULL
2.5	NULL
X	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
prevented	NULL
macrophages	NULL
from	NULL
inhibiting	NULL
germination	NULL
of	NULL
Aspergillus	NULL
spores	NULL
or	NULL
from	NULL
eliminating	NULL
ingested	NULL
bacteria	NULL
such	NULL
as	NULL
Listeria	NULL
,	NULL
Nocardia	NULL
,	NULL
or	NULL
Salmonella	NULL
.	NULL

Damage	NULL
to	NULL
macrophage	NULL
function	NULL
was	NULL
inhibited	NULL
by	NULL
progesterone	NULL
and	NULL
appeared	NULL
to	NULL
be	NULL
receptor-mediated	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
in	NULL
vivo	NULL
observations	NULL
,	NULL
dexamethasone	NULL
required	NULL
24-36	NULL
h	NULL
to	NULL
suppress	NULL
antimicrobial	NULL
activity	NULL
.	NULL

While	NULL
glucocorticoids	NULL
interfered	NULL
with	NULL
base-line	NULL
activity	NULL
of	NULL
macrophages	NULL
,	NULL
dexamethasone	NULL
concentrations	NULL
comparable	NULL
to	NULL
drug	NULL
levels	NULL
in	NULL
patients	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
macrophage	NULL
activation	NULL
.	NULL

Proliferating	NULL
lymphocytes	NULL
and	NULL
y-interferon	NULL
thus	NULL
increased	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
phagocytes	NULL
exposed	NULL
to	NULL
glucocorticoids	NULL
over	NULL
that	NULL
of	NULL
control	NULL
cells	NULL
.	NULL

Macrophage	NULL
activation	NULL
and	NULL
correction	NULL
of	NULL
the	NULL
dexamethasone	NULL
effect	NULL
by	NULL
y-interferon	NULL
,	NULL
however	NULL
,	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
pathogen	NULL
.	NULL

The	NULL
lymphokine	NULL
enhanced	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
dexamethasone-treated	NULL
macrophages	NULL
against	NULL
Listeria	NULL
and	NULL
Salmonella	NULL
but	NULL
not	NULL
against	NULL
Aspergillus	NULL
or	NULL
Nocardia	NULL
.	NULL

Dexameth-asone-induced	NULL
damage	NULL
to	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
human	NULL
macrophages	NULL
in	NULL
vitro	NULL
parallels	NULL
observations	NULL
that	NULL
glucocorticoids	NULL
render	NULL
laboratory	NULL
animals	NULL
susceptible	NULL
to	NULL
listeriosis	NULL
and	NULL
aspergillosis	NULL
by	NULL
damaging	NULL
resident	NULL
macrophages	NULL
.	NULL

Suppression	NULL
of	NULL
macrophage	NULL
antimicrobial	NULL
activity	NULL
should	NULL
thus	NULL
be	NULL
considered	NULL
when	NULL
treating	NULL
patients	NULL
with	NULL
glucocorticoids	NULL
;	NULL
its	NULL
prevention	NULL
by	NULL
y-interferon	NULL
might	NULL
be	NULL
beneficial	NULL
for	NULL
some	NULL
but	NULL
not	NULL
all	NULL
pathogens	NULL
.	NULL

Introduction	NULL
Observations	NULL
of	NULL
patients	NULL
undergoing	NULL
glucocorticoid	NULL
(	NULL
GC	NULL
)	NULL
therapy	NULL
(	NULL
1-3	NULL
)	NULL
or	NULL
suffering	NULL
from	NULL
Cushing	NULL
's	NULL
syndrome	NULL
(	NULL
4	NULL
)	NULL
have	NULL
established	NULL
that	NULL
GC	NULL
affect	NULL
host	NULL
resistance	NULL
to	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
microorganisms	NULL
.	NULL

GC	NULL
affect	NULL
cell-mediated	NULL
(	NULL
reviewed	NULL
in	NULL
5	NULL
,	NULL
6	NULL
)	NULL
and	NULL
hu-	NULL
Address	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Schaffner	NULL
,	NULL
Medizinische	NULL
Klinik	NULL
,	NULL
Room	NULL
CH	NULL
13	NULL
,	NULL
University	NULL
Hospital	NULL
CH-8091	NULL
,	NULL
Ziirich	NULL
,	NULL
Switzerland	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
22	NULL
February	NULL
1985	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
28	NULL
May	NULL
1985	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
y-IFN	NULL
,	NULL
gamma	NULL
interferon	NULL
;	NULL
CGD	NULL
,	NULL
chronic	NULL
granulomatous	NULL
disease	NULL
;	NULL
Con-A	NULL
,	NULL
Concanavalin	NULL
A	NULL
;	NULL
GBSS	NULL
,	NULL
Gey	NULL
's	NULL
balanced	NULL
salt	NULL
solution	NULL
;	NULL
GC	NULL
,	NULL
glucocorticoid	NULL
(	NULL
s	NULL
)	NULL
;	NULL
PPD	NULL
,	NULL
purified	NULL
protein	NULL
de-rivative	NULL
;	NULL
PS	NULL
,	NULL
Penicillin-Streptomycin	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/85/11/1755/10	NULL
$	NULL
1.00	NULL
Volume	NULL
76	NULL
,	NULL
November	NULL
1985	NULL
,	NULL
1755-1764	NULL
moral	NULL
immunity	NULL
(	NULL
6	NULL
)	NULL
as	NULL
well	NULL
as	NULL
phagocyte	NULL
function	NULL
(	NULL
reviewed	NULL
in	NULL
6	NULL
)	NULL
,	NULL
but	NULL
the	NULL
relative	NULL
contribution	NULL
of	NULL
individual	NULL
immunosuppressive	NULL
mechanisms	NULL
to	NULL
the	NULL
impairment	NULL
of	NULL
host	NULL
defense	NULL
has	NULL
not	NULL
been	NULL
defined	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
shown	NULL
in	NULL
mice	NULL
that	NULL
suppression	NULL
of	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
resident	NULL
macrophages	NULL
by	NULL
cortisone	NULL
is	NULL
critical	NULL
for	NULL
induction	NULL
of	NULL
overwhelming	NULL
infection	NULL
with	NULL
Aspergillus	NULL
(	NULL
7	NULL
)	NULL
and	NULL
Listeria	NULL
(	NULL
8	NULL
)	NULL
,	NULL
two	NULL
important	NULL
opportunistic	NULL
pathogens	NULL
.	NULL

The	NULL
concept	NULL
that	NULL
GC	NULL
affect	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
macrophage	NULL
to	NULL
kill	NULL
ingested	NULL
microorganisms	NULL
,	NULL
however	NULL
,	NULL
has	NULL
not	NULL
found	NULL
uniform	NULL
acceptance	NULL
because	NULL
confirmation	NULL
of	NULL
this	NULL
GC	NULL
effect	NULL
on	NULL
pure	NULL
phagocyte	NULL
preparations	NULL
is	NULL
lacking	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
,	NULL
exposure	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
to	NULL
GC	NULL
either	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
or	NULL
had	NULL
an	NULL
effect	NULL
only	NULL
at	NULL
GC	NULL
concentrations	NULL
of	NULL
16-100	NULL
ug/ml	NULL
(	NULL
11	NULL
)	NULL
,	NULL
concentrations	NULL
that	NULL
exceed	NULL
clinical	NULL
drug	NULL
levels	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
administration	NULL
of	NULL
GC	NULL
in	NULL
doses	NULL
of	NULL
100-500	NULL
mg	NULL
results	NULL
in	NULL
drug	NULL
levels	NULL
that	NULL
do	NULL
not	NULL
exceed	NULL
1-2	NULL
ug/ml	NULL
!	NULL

for	NULL
sustained	NULL
time	NULL
periods	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
peak	NULL
GC	NULL
level	NULL
of	NULL
20	NULL
ug/	NULL
ml	NULL
obtained	NULL
in	NULL
humans	NULL
after	NULL
infusion	NULL
of	NULL
1-2	NULL
g	NULL
of	NULL
methylpred-nisolone	NULL
(	NULL
Upjohn	NULL
Co.	NULL
,	NULL
Kalamazoo	NULL
,	NULL
MI	NULL
)	NULL
is	NULL
not	NULL
comparable	NULL
to	NULL
a	NULL
GC	NULL
concentration	NULL
of	NULL
16-100	NULL
ug/ml	NULL
in	NULL
cell	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
only	NULL
10	NULL
%	NULL
serum	NULL
(	NULL
11	NULL
)	NULL
,	NULL
since	NULL
in	NULL
vivo	NULL
about	NULL
90	NULL
%	NULL
of	NULL
the	NULL
drug	NULL
is	NULL
immobilized	NULL
by	NULL
albumin	NULL
and	NULL
thus	NULL
remains	NULL
biologically	NULL
inactive	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
Cushing	NULL
's	NULL
syndrome	NULL
,	NULL
severe	NULL
opportunistic	NULL
infections	NULL
such	NULL
as	NULL
asper-gillosis	NULL
,	NULL
nocardiosis	NULL
,	NULL
or	NULL
listeriosis	NULL
occur	NULL
at	NULL
cortisol	NULL
levels	NULL
ranging	NULL
from	NULL
0.4	NULL
to	NULL
1.8	NULL
ug/ml	NULL
!	NULL

(	NULL
4	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
while	NULL
animal	NULL
studies	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
15	NULL
)	NULL
indicate	NULL
that	NULL
GC	NULL
affect	NULL
the	NULL
ability	NULL
of	NULL
macrophages	NULL
to	NULL
kill	NULL
ingested	NULL
microorganisms	NULL
,	NULL
no	NULL
convincing	NULL
proof	NULL
exists	NULL
for	NULL
a	NULL
direct	NULL
steroid	NULL
effect	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
effects	NULL
of	NULL
therapeutic	NULL
GC	NULL
levels	NULL
on	NULL
the	NULL
process	NULL
of	NULL
macrophage	NULL
activation	NULL
by	NULL
lymphokines	NULL
are	NULL
controversial	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
mouse	NULL
peritoneal	NULL
macrophages	NULL
against	NULL
Toxoplasma	NULL
gondii	NULL
showed	NULL
that	NULL
hydrocortisone	NULL
succinate	NULL
in	NULL
a	NULL
concentration	NULL
of	NULL
100	NULL
ug/ml	NULL
prevented	NULL
macrophage	NULL
activation	NULL
by	NULL
lymphokines	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cortisol	NULL
in	NULL
concentrations	NULL
up	NULL
to	NULL
50	NULL
ug/ml	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
lym-phokine-mediated	NULL
suppression	NULL
of	NULL
bacterial	NULL
proliferation	NULL
in	NULL
human	NULL
alveolar	NULL
macrophages	NULL
and	NULL
blood-derived	NULL
macrophages	NULL
infected	NULL
with	NULL
Legionella	NULL
pneumophila	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Such	NULL
conflicting	NULL
evidence	NULL
prompted	NULL
this	NULL
reanalysis	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
GC	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
and	NULL
on	NULL
their	NULL
responsiveness	NULL
to	NULL
lymphokines	NULL
.	NULL

By	NULL
taking	NULL
into	NULL
account	NULL
that	NULL
receptor-mediated	NULL
(	NULL
hormonal	NULL
)	NULL
effects	NULL
of	NULL
GC	NULL
may	NULL
require	NULL
many	NULL
hours	NULL
for	NULL
expression	NULL
(	NULL
17	NULL
)	NULL
,	NULL
the	NULL
present	NULL
studies	NULL
characterize	NULL
a	NULL
dramatic	NULL
reduction	NULL
of	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
human	NULL
blood-derived	NULL
and	NULL
alveolar	NULL
macrophages	NULL
by	NULL
GC	NULL
.	NULL

Furthermore	NULL
,	NULL
they	NULL
suggest	NULL
that	NULL
GC-induced	NULL
damage	NULL
to	NULL
antimicrobial	NULL
function	NULL
of	NULL
macrophages	NULL
can	NULL
be	NULL
prevented	NULL
or	NULL
reverted	NULL
for	NULL
some	NULL
but	NULL
not	NULL
for	NULL
all	NULL
microorganisms	NULL
by	NULL
y-interferon	NULL
(	NULL
y-IFN	NULL
)	NULL
or	NULL
proliferating	NULL
lymphocytes	NULL
.	NULL

Glucocorticoid	NULL
Effect	NULL
on	NULL
Macrophages	NULL
-	NULL
1755	NULL
Methods	NULL
Organisms	NULL
.	NULL

A	NULL
lot	NULL
of	NULL
Listeria	NULL
monocytogenes	NULL
strain	NULL
EGD	NULL
kept	NULL
virulent	NULL
by	NULL
passages	NULL
through	NULL
mice	NULL
was	NULL
frozen	NULL
in	NULL
aliquots	NULL
of	NULL
2	NULL
ml	NULL
at	NULL
-70°C	NULL
.	NULL

Suspensions	NULL
of	NULL
Listeria	NULL
and	NULL
of	NULL
single	NULL
spores	NULL
of	NULL
A.	NULL
fumigatus	NULL
isolated	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
disseminated	NULL
aspergillosis	NULL
were	NULL
prepared	NULL
in	NULL
Gey	NULL
's	NULL
balanced	NULL
salt	NULL
solution	NULL
(	NULL
GBSS	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Strain	NULL
GUH-2	NULL
of	NULL
N.	NULL
asteroides	NULL
was	NULL
grown	NULL
in	NULL
brain	NULL
heart	NULL
infusion	NULL
broth	NULL
on	NULL
a	NULL
shaking	NULL
platform	NULL
overnight	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
GBSS	NULL
,	NULL
homogenized	NULL
with	NULL
teflon	NULL
pestles	NULL
,	NULL
and	NULL
filtered	NULL
through	NULL
cotton	NULL
gauze	NULL
to	NULL
give	NULL
a	NULL
suspension	NULL
of	NULL
coccoid	NULL
bacteria	NULL
or	NULL
rods	NULL
.	NULL

A	NULL
serum-resistant	NULL
strain	NULL
of	NULL
Salmonella	NULL
typhi-murium	NULL
,	NULL
originally	NULL
isolated	NULL
from	NULL
a	NULL
cow	NULL
,	NULL
was	NULL
grown	NULL
overnight	NULL
in	NULL
trypticase	NULL
soy	NULL
broth	NULL
.	NULL

Inocula	NULL
of	NULL
spores	NULL
and	NULL
bacteria	NULL
were	NULL
quantitated	NULL
by	NULL
the	NULL
pour	NULL
plate	NULL
technique	NULL
(	NULL
7	NULL
)	NULL
or	NULL
by	NULL
culturing	NULL
serial	NULL
dilutions	NULL
on	NULL
agar	NULL
plates	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Media	NULL
,	NULL
serum	NULL
,	NULL
and	NULL
reagents	NULL
.	NULL

Brain	NULL
heart	NULL
infusion	NULL
,	NULL
trypticase	NULL
soy	NULL
broth	NULL
,	NULL
trypticase	NULL
soy	NULL
agar	NULL
,	NULL
and	NULL
Sabouraud	NULL
dextrose	NULL
agar	NULL
were	NULL
all	NULL
from	NULL
Difco	NULL
Laboratories	NULL
,	NULL
Detroit	NULL
,	NULL
MI	NULL
.	NULL

Medium-199	NULL
(	NULL
M-199	NULL
)	NULL
,	NULL
GBSS	NULL
,	NULL
and	NULL
Penicillin-Streptomycin	NULL
(	NULL
PS	NULL
)	NULL
were	NULL
from	NULL
Gibco	NULL
Europe	NULL
(	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
,	NULL
dexamethasone	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
progesterone	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
and	NULL
cortisol	NULL
(	NULL
Calbiochem-Behring	NULL
Corp.	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
dissolved	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2.5	NULL
X	NULL
10~	NULL
mol/liter	NULL
in	NULL
absolute	NULL
ethanol	NULL
and	NULL
then	NULL
diluted	NULL
to	NULL
the	NULL
indicated	NULL
concentrations	NULL
in	NULL
M-199	NULL
.	NULL

Hydrocortisone	NULL
succinate	NULL
(	NULL
Upjohn	NULL
Co.	NULL
)	NULL
was	NULL
directly	NULL
dissolved	NULL
in	NULL
M-199	NULL
.	NULL

Pyrogen-free	NULL
human	NULL
recombinant	NULL
y-IFN	NULL
in	NULL
frozen	NULL
aliquots	NULL
of	NULL
1.2	NULL
X	NULL
10°	NULL
U/ml	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
L.	NULL
Gerlis	NULL
(	NULL
Biogen	NULL
SA	NULL
,	NULL
Geneva	NULL
,	NULL
Switzerland	NULL
)	NULL
,	NULL
defrosted	NULL
y-IFN	NULL
was	NULL
stored	NULL
at	NULL
4°C	NULL
not	NULL
longer	NULL
than	NULL
4	NULL
d.	NULL
Other	NULL
media	NULL
supplements	NULL
included	NULL
Cyclosporin	NULL
A	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
J.	NULL
F.	NULL
Borel	NULL
,	NULL
Sandoz	NULL
,	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
,	NULL
purified	NULL
protein	NULL
derivative	NULL
(	NULL
PPD	NULL
)	NULL
from	NULL
M.	NULL
ruberculosis	NULL
,	NULL
Statens	NULL
Serum	NULL
Institut	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
,	NULL
Concanavalin	NULL
A	NULL
(	NULL
Con	NULL
A	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
and	NULL
Tobramycin	NULL
(	NULL
Eli	NULL
Lilly	NULL
and	NULL
Co.	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Serum	NULL
from	NULL
normal	NULL
volunteers	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Mononuclear	NULL
phagocytes	NULL
.	NULL

Blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
normal	NULL
volunteers	NULL
and	NULL
three	NULL
patients	NULL
with	NULL
chronic	NULL
granulomatous	NULL
disease	NULL
of	NULL
childhood	NULL
(	NULL
courtesy	NULL
of	NULL
Dr.	NULL
R.	NULL
Seger	NULL
,	NULL
Children	NULL
's	NULL
Hospital	NULL
,	NULL
University	NULL
of	NULL
Ziirich	NULL
)	NULL
were	NULL
separated	NULL
by	NULL
the	NULL
Ficoll-Hypaque	NULL
technique	NULL
and	NULL
monolayers	NULL
were	NULL
prepared	NULL
on	NULL
12-mm	NULL
glass	NULL
coverslips	NULL
by	NULL
a	NULL
slight	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Nagakawara	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
as	NULL
fully	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Alveolar	NULL
macrophages	NULL
were	NULL
obtained	NULL
by	NULL
lavage	NULL
of	NULL
the	NULL
lung	NULL
with	NULL
3	NULL
X	NULL
50	NULL
ml	NULL
of	NULL
saline	NULL
through	NULL
a	NULL
wedged	NULL
fiberoptic	NULL
bronchoscope	NULL
(	NULL
courtesy	NULL
of	NULL
Dr.	NULL
E.	NULL
Russi	NULL
,	NULL
University	NULL
Hospital	NULL
,	NULL
Ziirich	NULL
)	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
the	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
without	NULL
pulmonary	NULL
pathology	NULL
,	NULL
and	NULL
a	NULL
patient	NULL
with	NULL
limited	NULL
lung	NULL
cancer	NULL
.	NULL

After	NULL
filtration	NULL
through	NULL
two	NULL
layers	NULL
of	NULL
loose	NULL
cotton	NULL
gauze	NULL
,	NULL
the	NULL
cell	NULL
yield	NULL
was	NULL
2-4	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
with	NULL
>	NULL
95	NULL
%	NULL
viable	NULL
macrophages	NULL
(	NULL
Trypan	NULL
Blue	NULL
,	NULL
Giemsa	NULL
)	NULL
.	NULL

Monolayers	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
and	NULL
alveolar	NULL
macrophages	NULL
were	NULL
obtained	NULL
by	NULL
placing	NULL
0.1	NULL
ml	NULL
of	NULL
a	NULL
suspension	NULL
with	NULL
1.5	NULL
X	NULL
10°	NULL
and	NULL
3	NULL
X	NULL
10	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
washed	NULL
cells	NULL
per	NULL
ml	NULL
of	NULL
M-199	NULL
supplemented	NULL
with	NULL
25	NULL
%	NULL
human	NULL
serum	NULL
on	NULL
12-mm	NULL
coverslips	NULL
placed	NULL
in	NULL
35-mm	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
Falcon	NULL
Plastics	NULL
,	NULL
Oxnard	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
for	NULL
adhesion	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
,	NULL
coverslips	NULL
were	NULL
washed	NULL
four	NULL
times	NULL
with	NULL
prewarmed	NULL
GBSS	NULL
,	NULL
transferred	NULL
into	NULL
16-mm	NULL
diam	NULL
plastic	NULL
cluster	NULL
plates	NULL
(	NULL
Falcon	NULL
Plastics	NULL
)	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
M-199	NULL
supplemented	NULL
with	NULL
25	NULL
%	NULL
human	NULL
serum	NULL
and	NULL
with	NULL
steroids	NULL
,	NULL
y-IFN	NULL
,	NULL
lymphocytes	NULL
,	NULL
or	NULL
other	NULL
additives	NULL
as	NULL
indicated	NULL
.	NULL

Where	NULL
ap-propriate	NULL
,	NULL
equivalent	NULL
amounts	NULL
of	NULL
solvents	NULL
were	NULL
added	NULL
to	NULL
control	NULL
wells	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
for	NULL
steroids	NULL
,	NULL
ethanol	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
<	NULL
0.1	NULL
%	NULL
0	NULL
)	NULL
.	NULL

Monolayers	NULL
always	NULL
consisted	NULL
of	NULL
>	NULL
98	NULL
%	NULL
mononuclear	NULL
phagocytes	NULL
as	NULL
determined	NULL
by	NULL
Giemsa	NULL
stain	NULL
and	NULL
phagocytosis	NULL
of	NULL
Aspergillus	NULL
spores	NULL
.	NULL

For	NULL
experiments	NULL
with	NULL
Aspergillus	NULL
,	NULL
PS	NULL
(	NULL
50	NULL
U/ml	NULL
and	NULL
50	NULL
ug/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
medium	NULL
.	NULL

Medium	NULL
supplemented	NULL
with	NULL
the	NULL
appropriate	NULL
drugs	NULL
and	NULL
reagents	NULL
was	NULL
changed	NULL
daily	NULL
throughout	NULL
the	NULL
experiments	NULL
.	NULL

Secretion	NULL
of	NULL
lysozyme	NULL
by	NULL
macrophage	NULL
monolayers	NULL
was	NULL
assayed	NULL
in	NULL
supernatants	NULL
with	NULL
Micrococcus	NULL
lysodeiktiticus	NULL
cell	NULL
walls	NULL
as	NULL
substrate	NULL
and	NULL
compared	NULL
with	NULL
egg	NULL
white	NULL
lysozyme	NULL
standards	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Lysozyme	NULL
background	NULL
activity	NULL
(	NULL
1-2	NULL
ug/ml	NULL
)	NULL
of	NULL
medium	NULL
supplemented	NULL
with	NULL
25	NULL
%	NULL
serum	NULL
was	NULL
subtracted	NULL
.	NULL

Assay	NULL
for	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

Suppression	NULL
of	NULL
germination	NULL
of	NULL
spores	NULL
from	NULL
Aspergillus	NULL
ingested	NULL
by	NULL
macrophages	NULL
was	NULL
assayed	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
as	NULL
fully	NULL
described	NULL
previously	NULL
(	NULL
7	NULL
,	NULL
18	NULL
)	NULL
.	NULL

1756	NULL
_	NULL
A.	NULL
Schaffner	NULL
Germination	NULL
rates	NULL
of	NULL
spores	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
spores	NULL
forming	NULL
mycelia	NULL
among	NULL
200	NULL
counted	NULL
per	NULL
coverslip	NULL
from	NULL
four	NULL
coverslips	NULL
.	NULL

The	NULL
germination	NULL
rate	NULL
of	NULL
spores	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
was	NULL
not	NULL
influenced	NULL
by	NULL
the	NULL
steroids	NULL
or	NULL
y-IFN	NULL
and	NULL
was	NULL
always	NULL
>	NULL
95	NULL
%	NULL
at	NULL
24	NULL
h.	NULL
The	NULL
antibacterial	NULL
activity	NULL
of	NULL
macrophages	NULL
was	NULL
quantitated	NULL
by	NULL
monitoring	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
infected	NULL
over	NULL
time	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
monolayers	NULL
were	NULL
challenged	NULL
with	NULL
2-5	NULL
x	NULL
10	NULL
'	NULL
bacteria	NULL
suspended	NULL
in	NULL
GBSS	NULL
per	NULL
coverslip	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
bacteria	NULL
,	NULL
washed	NULL
four	NULL
times	NULL
by	NULL
gentle	NULL
rocking	NULL
with	NULL
prewarmed	NULL
GBSS	NULL
,	NULL
and	NULL
then	NULL
further	NULL
incubated	NULL
in	NULL
complete	NULL
medium	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

In	NULL
experiments	NULL
with	NULL
Listeria	NULL
,	NULL
if	NULL
not	NULL
stated	NULL
otherwise	NULL
,	NULL
tobramycin	NULL
in	NULL
a	NULL
bacteriostatic	NULL
concentration	NULL
of	NULL
1.2	NULL
ug/ml	NULL
was	NULL
added	NULL
to	NULL
the	NULL
medium	NULL
after	NULL
phagocytosis	NULL
,	NULL
to	NULL
prevent	NULL
continuous	NULL
infection	NULL
of	NULL
macrophages	NULL
by	NULL
extracellularly	NULL
replicating	NULL
bacteria	NULL
.	NULL

An	NULL
aminoglycoside	NULL
was	NULL
chosen	NULL
because	NULL
of	NULL
its	NULL
minimal	NULL
antimicrobial	NULL
activity	NULL
within	NULL
phagocytes	NULL
.	NULL

At	NULL
indicated	NULL
times	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
aspirated	NULL
,	NULL
coverslips	NULL
were	NULL
rapidly	NULL
dried	NULL
in	NULL
a	NULL
laminar	NULL
air	NULL
flow	NULL
,	NULL
and	NULL
stained	NULL
by	NULL
the	NULL
May-Giemsa-Griinwald	NULL
method	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
with	NULL
intracellular	NULL
bacteria	NULL
was	NULL
then	NULL
enumerated	NULL
among	NULL
800	NULL
cells	NULL
from	NULL
quadruplicate	NULL
coverslips	NULL
discriminating	NULL
in	NULL
addition	NULL
between	NULL
cells	NULL
with	NULL
1-10	NULL
and	NULL
>	NULL
10	NULL
bacteria	NULL
per	NULL
cell	NULL
.	NULL

This	NULL
limit	NULL
was	NULL
chosen	NULL
because	NULL
cells	NULL
always	NULL
contained	NULL
<	NULL
10	NULL
bacteria	NULL
immediately	NULL
after	NULL
phagocytosis	NULL
and	NULL
bacterial	NULL
counts	NULL
above	NULL
10	NULL
per	NULL
cell	NULL
thus	NULL
reflected	NULL
intracellular	NULL
replication	NULL
of	NULL
bacteria	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

Small	NULL
differences	NULL
between	NULL
mean	NULL
values	NULL
were	NULL
evaluated	NULL
for	NULL
statistical	NULL
significance	NULL
by	NULL
f	NULL
test	NULL
.	NULL

Dose	NULL
and	NULL
time	NULL
dependency	NULL
of	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

For	NULL
a	NULL
first	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
monolayers	NULL
of	NULL
blood-derived	NULL
and	NULL
alveolar	NULL
macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
to	NULL
2.5	NULL
X	NULL
107	NULL
to	NULL
2.5	NULL
x	NULL
10-'°	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
and	NULL
then	NULL
challenged	NULL
with	NULL
spores	NULL
from	NULL
Aspergillus	NULL
fumigatus	NULL
.	NULL

The	NULL
antifungal	NULL
activity	NULL
of	NULL
the	NULL
phagocytes	NULL
was	NULL
quantitated	NULL
by	NULL
enumerating	NULL
the	NULL
number	NULL
of	NULL
spores	NULL
germinating	NULL
and	NULL
transforming	NULL
into	NULL
mycelia	NULL
24	NULL
h	NULL
after	NULL
phago-cytosis	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
spores	NULL
not	NULL
germinating	NULL
within	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
have	NULL
been	NULL
killed	NULL
by	NULL
the	NULL
macrophage	NULL
while	NULL
germinating	NULL
spores	NULL
escape	NULL
growth	NULL
inhibition	NULL
and	NULL
killing	NULL
(	NULL
7	NULL
,	NULL
18	NULL
)	NULL
.	NULL

A	NULL
full	NULL
suppression	NULL
of	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
was	NULL
seen	NULL
over	NULL
a	NULL
wide	NULL
dose	NULL
range	NULL
from	NULL
2.5	NULL
X	NULL
10~°	NULL
to	NULL
2.5	NULL
X	NULL
107°	NULL
mol/liter	NULL
(	NULL
9	NULL
ug/ml	NULL
to	NULL
9	NULL
ng/ml	NULL
)	NULL
of	NULL
dexamethasone	NULL
with	NULL
an	NULL
approximately	NULL
50	NULL
%	NULL
inhibitory	NULL
effect	NULL
at	NULL
2.5	NULL
X	NULL
10~°	NULL
mol/	NULL
liter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
at	NULL
dexamethasone	NULL
concentrations	NULL
well	NULL
into	NULL
the	NULL
usual	NULL
therapeutic	NULL
dose	NULL
range	NULL
,	NULL
a	NULL
maximum	NULL
suppressive	NULL
effect	NULL
was	NULL
noted	NULL
,	NULL
which	NULL
could	NULL
not	NULL
be	NULL
further	NULL
enhanced	NULL
by	NULL
exposure	NULL
to	NULL
yet	NULL
higher	NULL
GC	NULL
concentrations	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
monolayers	NULL
consisted	NULL
of	NULL
>	NULL
98	NULL
%	NULL
macrophages	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
Giesma	NULL
morphology	NULL
and	NULL
phagocytosis	NULL
of	NULL
aspergillus	NULL
spores	NULL
,	NULL
indicated	NULL
that	NULL
the	NULL
observed	NULL
GC	NULL
effect	NULL
was	NULL
not	NULL
mediated	NULL
by	NULL
contaminating	NULL
lymphocytes	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
by	NULL
demonstrating	NULL
that	NULL
(	NULL
a	NULL
)	NULL
substitution	NULL
of	NULL
culture	NULL
medium	NULL
by	NULL
supernatant	NULL
transferred	NULL
daily	NULL
from	NULL
autologous	NULL
monolayers	NULL
put	NULL
in	NULL
culture	NULL
!	NULL

d	NULL
earlier	NULL
in	NULL
dexa-methasone-free	NULL
medium	NULL
did	NULL
not	NULL
modulate	NULL
the	NULL
GC	NULL
effect	NULL
,	NULL
(	NULL
b	NULL
)	NULL
that	NULL
alveolar	NULL
macrophages	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
the	NULL
acquired	NULL
im-munodeficiency	NULL
syndrome	NULL
without	NULL
detectable	NULL
lymphocytes	NULL
in	NULL
the	NULL
cell	NULL
preparation	NULL
were	NULL
equally	NULL
susceptible	NULL
to	NULL
dexamethasone	NULL
as	NULL
were	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
,	NULL
and	NULL
(	NULL
c	NULL
)	NULL
that	NULL
1	NULL
ug/ml	NULL
of	NULL
cyclosporin	NULL
A	NULL
,	NULL
which	NULL
blocks	NULL
the	NULL
production	NULL
of	NULL
lymphokines	NULL
,	NULL
notably	NULL
that	NULL
of	NULL
y-IFN	NULL
(	NULL
21	NULL
)	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
``	NULL
young	NULL
``	NULL
blood-derived	NULL
macrophages	NULL
were	NULL
as	NULL
susceptible	NULL
to	NULL
dexamethasone	NULL
as	NULL
were	NULL
tissue	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
)	NULL
,	NULL
which	NULL
indicates	NULL
that	NULL
the	NULL
effect	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
solely	NULL
by	NULL
a	NULL
hormonal	NULL
modulation	NULL
of	NULL
the	NULL
differentiation	NULL
of	NULL
blood	NULL
monocytes	NULL
into	NULL
tissue	NULL
macrophages	NULL
.	NULL

GERMINATION	NULL
RATE	NULL
(	NULL
%	NULL
)	NULL
-	NULL
-	NULL
-7	NULL
-8	NULL
-9	NULL
-10	NULL
16°	NULL
046°	NULL
16	NULL
10	NULL
10	NULL
10	NULL
)	NULL
DEXAMETHASONE	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
x2.5	NULL
)	NULL
Figure	NULL
1	NULL
A.	NULL
Dose-dependent	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
macrophages	NULL
against	NULL
Aspergillus	NULL
spores	NULL
.	NULL

Macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
before	NULL
challenge	NULL
to	NULL
graded	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
.	NULL

Germination	NULL
rates	NULL
of	NULL
spores	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
by	NULL
blood-derived	NULL
(	NULL
-	NULL
)	NULL
and	NULL
alveolar	NULL
(	NULL
--	NULL
-	NULL
)	NULL
macrophages	NULL
are	NULL
given	NULL
from	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

Each	NULL
data	NULL
point	NULL
represents	NULL
the	NULL
mean	NULL
value	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
an	NULL
independent	NULL
experiment	NULL
;	NULL
SD	NULL
is	NULL
given	NULL
for	NULL
the	NULL
highest	NULL
dexamethasone	NULL
concentration	NULL
and	NULL
the	NULL
ethanol	NULL
control	NULL
.	NULL

Alveolar	NULL
macrophages	NULL
were	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
(	NULL
e	NULL
)	NULL
and	NULL
a	NULL
patient	NULL
with	NULL
the	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
(	NULL
@	NULL
)	NULL
.	NULL

807	NULL
®	NULL
0	NULL
I	NULL
GERMINATION	NULL
RATE	NULL
(	NULL
%	NULL
)	NULL
$	NULL
ho	NULL
O	NULL
1	NULL
T	NULL
T	NULL
T	NULL
I	NULL
¥	NULL
U	NULL
16°	NULL
16	NULL
``	NULL
16°	NULL
16°	NULL
16	NULL
``	NULL
°	NULL
3	NULL
GLUCOCORTICOID	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
x	NULL
2.5	NULL
)	NULL
Figure	NULL
1	NULL
C.	NULL
Suppression	NULL
of	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
is	NULL
receptor-mediated	NULL
.	NULL

Glucocorticoid	NULL
antagonism	NULL
by	NULL
progesterone	NULL
and	NULL
relation	NULL
of	NULL
the	NULL
suppressive	NULL
potency	NULL
of	NULL
dexamethasone	NULL
and	NULL
cortisol	NULL
.	NULL

Germination	NULL
rates	NULL
of	NULL
spores	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
by	NULL
blood-derived	NULL
macrophages	NULL
cultured	NULL
for	NULL
36	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
variable	NULL
dexamethasone	NULL
concentrations	NULL
(	NULL
e	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2.5	NULL
X	NULL
10~°	NULL
mol/liter	NULL
of	NULL
progesterone	NULL
plus	NULL
dexamethasone	NULL
(	NULL
#	NULL
)	NULL
,	NULL
or	NULL
cortisol	NULL
(	NULL
a	NULL
)	NULL
.	NULL

Mean+SD	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
.	NULL

80	NULL
%	NULL
)	NULL
(	NULL
407	NULL
GERMINATION	NULL
RATE	NULL
204	NULL
4	NULL
4	NULL
A	NULL
1	NULL
36	NULL
24	NULL
12	NULL
6	NULL
d	NULL
none	NULL
Start	NULL
of	NULL
Dexamethasone	NULL
Exposure	NULL
(	NULL
hours	NULL
before	NULL
challenge	NULL
)	NULL
Figure	NULL
1	NULL
B	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

Blood-derived	NULL
macrophages	NULL
were	NULL
exposed	NULL
to	NULL
2.5	NULL
X	NULL
107	NULL
``	NULL
moll/liter	NULL
of	NULL
dexamethasone	NULL
for	NULL
variable	NULL
time	NULL
periods	NULL
before	NULL
challenge	NULL
with	NULL
spores	NULL
.	NULL

Each	NULL
data	NULL
point	NULL
represents	NULL
the	NULL
mean	NULL
value	NULL
of	NULL
the	NULL
germination	NULL
rate+SD	NULL
from	NULL
quadruplicate	NULL
wells	NULL
;	NULL
results	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

D	NULL
80+	NULL
t	NULL
4	NULL
1	NULL
€	NULL
60	NULL
z	NULL
o	NULL
a	NULL
z	NULL
404	NULL
a	NULL
&	NULL
u	NULL
5	NULL
204	NULL
le	NULL
usm	NULL
o	NULL
0	NULL
[	NULL
20	NULL
10	NULL
16	NULL
10	NULL
10	NULL
10	NULL
G	NULL
DEXAMETHASONE	NULL
x2.5	NULL
)	NULL
Figure	NULL
1	NULL
D.	NULL
The	NULL
dexamethasone	NULL
effect	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
does	NULL
not	NULL
depend	NULL
on	NULL
oxidative	NULL
killing	NULL
mechanisms	NULL
.	NULL

The	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
(	NULL
e	NULL
)	NULL
and	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
chronic	NULL
granulomatous	NULL
disease	NULL
of	NULL
childhood	NULL
(	NULL
a	NULL
)	NULL
were	NULL
compared	NULL
after	NULL
culture	NULL
of	NULL
phagocytes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
variable	NULL
dexamethasone	NULL
concentrations	NULL
for	NULL
36	NULL
h.	NULL
Mean+SD	NULL
of	NULL
germination	NULL
rates	NULL
of	NULL
spores	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
from	NULL
quadruplicate	NULL
wells	NULL
.	NULL

Glucocorticoid	NULL
Effect	NULL
on	NULL
Macrophages	NULL
-	NULL
1757	NULL
A	NULL
36-h	NULL
time	NULL
period	NULL
was	NULL
initially	NULL
selected	NULL
for	NULL
incubation	NULL
with	NULL
GC	NULL
based	NULL
on	NULL
our	NULL
previous	NULL
finding	NULL
in	NULL
experimental	NULL
aspergillosis	NULL
that	NULL
mice	NULL
had	NULL
to	NULL
be	NULL
given	NULL
cortisone	NULL
acetate	NULL
at	NULL
least	NULL
36	NULL
h	NULL
before	NULL
challenge	NULL
to	NULL
achieve	NULL
a	NULL
maximum	NULL
suppression	NULL
of	NULL
the	NULL
sporicidal	NULL
activity	NULL
of	NULL
macrophages	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
an	NULL
assessment	NULL
of	NULL
the	NULL
time	NULL
dependency	NULL
of	NULL
the	NULL
dexamethasone	NULL
effect	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
in	NULL
vitro	NULL
indicated	NULL
that	NULL
only	NULL
a	NULL
steroid	NULL
exposure	NULL
for	NULL
24	NULL
h	NULL
or	NULL
longer	NULL
resulted	NULL
in	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
the	NULL
antifungal	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
was	NULL
maximal	NULL
at	NULL
36	NULL
h	NULL
,	NULL
since	NULL
exposure	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
for	NULL
up	NULL
to	NULL
84	NULL
h	NULL
did	NULL
not	NULL
further	NULL
increase	NULL
the	NULL
germination	NULL
rate	NULL
of	NULL
ingested	NULL
spores	NULL
(	NULL
germination	NULL
after	NULL
36	NULL
h	NULL
of	NULL
dexamethasone	NULL
:	NULL
86+4	NULL
%	NULL
compared	NULL
with	NULL
84+3	NULL
%	NULL
after	NULL
84	NULL
h	NULL
,	NULL
P	NULL
>	NULL
0.05	NULL
)	NULL
.	NULL

Demonstration	NULL
that	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
is	NULL
receptor-mediated	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
maximum	NULL
suppression	NULL
of	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
occurred	NULL
at	NULL
dexamethasone	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
2.5	NULL
X	NULL
10~	NULL
mol/liter	NULL
indicated	NULL
that	NULL
the	NULL
effect	NULL
was	NULL
mediated	NULL
by	NULL
cytoplasmic	NULL
high-affinity	NULL
receptors	NULL
for	NULL
steroids	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
by	NULL
showing	NULL
that	NULL
a	NULL
10-1,000-fold	NULL
excess	NULL
of	NULL
progesterone	NULL
,	NULL
which	NULL
is	NULL
an	NULL
antagonist	NULL
of	NULL
GC	NULL
at	NULL
the	NULL
receptor	NULL
(	NULL
17	NULL
,	NULL
22	NULL
)	NULL
,	NULL
progressively	NULL
inhibited	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

Progesterone	NULL
itself	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
and	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
germination	NULL
rate	NULL
of	NULL
spores	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
when	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
cortisol	NULL
,	NULL
cortisol	NULL
turned	NULL
out	NULL
to	NULL
be	NULL
~10	NULL
times	NULL
less	NULL
potent	NULL
than	NULL
dexamethasone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
,	NULL
as	NULL
expected	NULL
for	NULL
a	NULL
receptor-mediated	NULL
GC	NULL
effect	NULL
in	NULL
vitro	NULL
(	NULL
22	NULL
)	NULL
.	NULL

70	NULL
50	NULL
%	NULL
Cells	NULL
Infected	NULL
304	NULL
107	NULL
Hours	NULL
after	NULL
Phagocytosis	NULL
Figure	NULL
2	NULL
.	NULL

Destruction	NULL
of	NULL
Listeria	NULL
monocytogenes	NULL
phagocytized	NULL
by	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
with	NULL
cell-associated	NULL
bacteria	NULL
was	NULL
enumerated	NULL
immediately	NULL
after	NULL
incubation	NULL
for	NULL
phagocytosis	NULL
and	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
by	NULL
washing	NULL
and	NULL
after	NULL
eight	NULL
and	NULL
14	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
#	NULL
)	NULL
,	NULL
control	NULL
cells	NULL
;	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
cells	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
before	NULL
phagocytosis	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
;	NULL
(	NULL
e	NULL
)	NULL
,	NULL
cells	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
to	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
;	NULL
(	NULL
a	NULL
)	NULL
,	NULL
cells	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
simultaneously	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
2.5	NULL
X	NULL
107	NULL
``	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
and	NULL
48	NULL
U/ml	NULL
!	NULL

of	NULL
y-IFN	NULL
.	NULL

There	NULL
were	NULL
no	NULL
significant	NULL
differences	NULL
in	NULL
phagocytosis	NULL
between	NULL
the	NULL
different	NULL
cell	NULL
preparations	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
for	NULL
differences	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
infected	NULL
at	NULL
0	NULL
h	NULL
;	NULL
comparable	NULL
number	NULL
of	NULL
bacteria	NULL
[	NULL
0-4	NULL
]	NULL
per	NULL
cell	NULL
)	NULL
.	NULL

At	NULL
8	NULL
h	NULL
,	NULL
11+1	NULL
%	NULL
of	NULL
dexamethasone-exposed	NULL
cells	NULL
harbored	NULL
>	NULL
10	NULL
bacteria/cell	NULL
compared	NULL
with	NULL
0	NULL
%	NULL
in	NULL
all	NULL
other	NULL
groups	NULL
and	NULL
at	NULL
14	NULL
h	NULL
this	NULL
difference	NULL
widened	NULL
to	NULL
48.5	NULL
%	NULL
vs.	NULL
0-1.25	NULL
%	NULL
.	NULL

of	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
with	NULL
visible	NULL
bacteria	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

1758	NULL
-	NULL
4	NULL
.	NULL

Schaffner	NULL
``	NULL
Tno	NULL
ap	NULL
Static	NULL
Ab	NULL
Cidal	NULL
Ab	NULL
IF	NULL
%	NULL
CELLS	NULL
INFECTED	NULL
8	NULL
ZZZ	NULL
l	NULL
ho	NULL
o	NULL
r	NULL
+	NULL
C	NULL
D+	NULL
D	NULL
C	NULL
D+l	NULL
D	NULL
C	NULL
D+l	NULL
D	NULL
Figure	NULL
3	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
various	NULL
aminoglycoside	NULL
concentrations	NULL
on	NULL
the	NULL
antibacterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

After	NULL
challenge	NULL
of	NULL
macrophages	NULL
with	NULL
Listeria	NULL
and	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
from	NULL
monolayers	NULL
by	NULL
washing	NULL
,	NULL
no	NULL
antibiotic	NULL
(	NULL
no	NULL
Ab	NULL
)	NULL
,	NULL
a	NULL
bacteriostatic	NULL
concentration	NULL
of	NULL
1.2	NULL
ug/ml	NULL
(	NULL
static	NULL
Ab	NULL
)	NULL
,	NULL
or	NULL
a	NULL
bactericidal	NULL
concentration	NULL
of	NULL
10	NULL
ug/ml	NULL
of	NULL
Tobramycin	NULL
(	NULL
cidal	NULL
Ab	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
medium	NULL
.	NULL

The	NULL
antibiotic	NULL
prevented	NULL
extracellular	NULL
multiplication	NULL
of	NULL
bacteria	NULL
and	NULL
continuous	NULL
infection	NULL
during	NULL
incubation	NULL
without	NULL
altering	NULL
the	NULL
relation	NULL
between	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
control	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
dexamethasone	NULL
(	NULL
D	NULL
)	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
dexamethasone	NULL
and	NULL
y-IFN	NULL
(	NULL
D	NULL
+	NULL
I	NULL
)	NULL
.	NULL

Macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
M	NULL
of	NULL
dexamethasone	NULL
and	NULL
to	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
.	NULL

The	NULL
height	NULL
of	NULL
the	NULL
columns	NULL
represents	NULL
the	NULL
mean	NULL
value+SD	NULL
of	NULL
cells	NULL
infected	NULL
after	NULL
incubation	NULL
for	NULL
8	NULL
h	NULL
after	NULL
phagocytosis	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

The	NULL
infection	NULL
rate	NULL
of	NULL
cells	NULL
immediately	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
was	NULL
52.5	NULL
%	NULL
with	NULL
no	NULL
significant	NULL
difference	NULL
among	NULL
different	NULL
cell	NULL
preparations	NULL
.	NULL

Exclusion	NULL
of	NULL
nonspecific	NULL
toxicity	NULL
of	NULL
glucocorticoids	NULL
.	NULL

Neither	NULL
cortisol	NULL
nor	NULL
dexamethasone	NULL
in	NULL
a	NULL
concentration	NULL
up	NULL
to	NULL
2.5	NULL
X	NULL
10-5	NULL
mol/liter	NULL
affected	NULL
the	NULL
cell	NULL
density	NULL
of	NULL
the	NULL
monolayers	NULL
as	NULL
judged	NULL
by	NULL
phase	NULL
contrast	NULL
microscopy	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
>	NULL
96	NULL
%	NULL
after	NULL
all	NULL
regimens	NULL
as	NULL
determined	NULL
in	NULL
several	NULL
experiments	NULL
immediately	NULL
after	NULL
challenge	NULL
by	NULL
Trypan	NULL
Blue	NULL
exclusion	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
between	NULL
the	NULL
phagocytic	NULL
index	NULL
of	NULL
glucocorticoid	NULL
treated	NULL
or	NULL
control	NULL
cells	NULL
in	NULL
experiments	NULL
with	NULL
spores	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
subsequent	NULL
experiments	NULL
with	NULL
bacteria	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
8	NULL
)	NULL
,	NULL
indicating	NULL
preserved	NULL
phagocytic	NULL
function	NULL
after	NULL
dexamethasone	NULL
or	NULL
cortisol	NULL
exposure	NULL
.	NULL

To	NULL
further	NULL
exclude	NULL
nonspecific	NULL
toxicity	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
GC	NULL
on	NULL
anabolic	NULL
function	NULL
in	NULL
two	NULL
experiments	NULL
with	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

Lysozyme	NULL
was	NULL
selected	NULL
as	NULL
marker	NULL
,	NULL
because	NULL
synthesis	NULL
and	NULL
secretion	NULL
of	NULL
this	NULL
enzyme	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
independent	NULL
from	NULL
GC-modulation	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Monolayers	NULL
cultured	NULL
in	NULL
medium	NULL
with	NULL
2.5	NULL
X	NULL
10~°	NULL
,	NULL
2.5	NULL
X	NULL
107	NULL
``	NULL
,	NULL
or	NULL
2.5	NULL
X	NULL
107	NULL
``	NULL
moll/liter	NULL
of	NULL
dexamethasone	NULL
for	NULL
48	NULL
h	NULL
secreted	NULL
in	NULL
the	NULL
continuous	NULL
presence	NULL
of	NULL
the	NULL
steroid	NULL
6.6+0.5	NULL
,	NULL
6.8+0.4	NULL
,	NULL
and	NULL
6.6+0.5	NULL
ug	NULL
of	NULL
lysozyme	NULL
per	NULL
coverslip	NULL
within	NULL
the	NULL
next	NULL
18	NULL
h	NULL
(	NULL
mean+SD	NULL
from	NULL
quadruplicate	NULL
wells	NULL
)	NULL
compared	NULL
with	NULL
6.8+0.6	NULL
ug/coverslip	NULL
secreted	NULL
by	NULL
control	NULL
cells	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
for	NULL
all	NULL
differences	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
monolayers	NULL
exposed	NULL
to	NULL
cortisol	NULL
in	NULL
concentrations	NULL
up	NULL
to	NULL
2.5	NULL
X	NULL
107°	NULL
mol/liter	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Suppression	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
macrophages	NULL
against	NULL
spores	NULL
by	NULL
dexamethasone	NULL
is	NULL
independent	NULL
from	NULL
oxidative	NULL
killing	NULL
systems	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
inhibition	NULL
and	NULL
killing	NULL
of	NULL
spores	NULL
from	NULL
Aspergilli	NULL
by	NULL
macrophages	NULL
is	NULL
independent	NULL
from	NULL
oxidative	NULL
killing	NULL
mechanisms	NULL
(	NULL
18	NULL
)	NULL
.	NULL

By	NULL
comparing	NULL
the	NULL
activity	NULL
of	NULL
macro	NULL
INFECTED	NULL
%	NULL
CELLS	NULL
16	NULL
``	NULL
10°	NULL
10°	NULL
10°	NULL
J	NULL
DEXAMETHASONE	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
x	NULL
2.5	NULL
)	NULL
Figure	NULL
4	NULL
A	NULL
.	NULL

Dose	NULL
dependent	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
and	NULL
antagonism	NULL
of	NULL
the	NULL
glucocorticoid	NULL
effect	NULL
by	NULL
progesterone	NULL
.	NULL

Blood-derived	NULL
macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
before	NULL
challenge	NULL
to	NULL
graded	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
#	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
e	NULL
)	NULL
of	NULL
2.5	NULL
X	NULL
mol/liter	NULL
of	NULL
progesterone	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
infected	NULL
immediately	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
was	NULL
uniform	NULL
at	NULL
all	NULL
dexamethasone	NULL
and/or	NULL
progesterone	NULL
concentrations	NULL
and	NULL
was	NULL
67.5	NULL
%	NULL
with	NULL
0-5	NULL
bacteria/cell	NULL
.	NULL

Mean+SD	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
harboring	NULL
bacteria	NULL
8	NULL
h	NULL
after	NULL
phagocytosis	NULL
from	NULL
one	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

C	NULL
so+	NULL
A	NULL
R	NULL
40+	NULL
e	NULL
lu	NULL
lt	NULL
<	NULL
t	NULL
_	NULL
_	NULL
w	NULL
o	NULL
l	NULL
Q	NULL
20	NULL
36	NULL
24	NULL
12	NULL
6	NULL
-	NULL
0	NULL
___	NULL
none	NULL
Start	NULL
of	NULL
Dexamethasone	NULL
Exposure	NULL
{	NULL
hours	NULL
before	NULL
challenge	NULL
)	NULL
Figure	NULL
4	NULL
C.	NULL
Time	NULL
course	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

Relation	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
unable	NULL
to	NULL
clear	NULL
ingested	NULL
bacteria	NULL
to	NULL
the	NULL
duration	NULL
of	NULL
exposure	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
mean+SD	NULL
of	NULL
the	NULL
percent	NULL
cells	NULL
infected	NULL
8	NULL
h	NULL
after	NULL
phagocytosis	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

Immediately	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
,	NULL
58	NULL
%	NULL
(	NULL
experiment	NULL
1	NULL
)	NULL
and	NULL
61.5	NULL
%	NULL
(	NULL
experiment	NULL
2	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
cells	NULL
were	NULL
associated	NULL
with	NULL
Listeria	NULL
(	NULL
0-4/cell	NULL
)	NULL
.	NULL

507	NULL
301	NULL
%	NULL
CELLS	NULL
INFECTED	NULL
10	NULL
105	NULL
106	NULL
iof	NULL
108	NULL
10°	NULL
101°	NULL
g	NULL
GLUCOCORTICOID	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
x	NULL
2.5	NULL
)	NULL
Figure	NULL
4	NULL
B	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
relative	NULL
potency	NULL
of	NULL
dexamethasone	NULL
,	NULL
cortisol	NULL
,	NULL
and	NULL
hydrocortisone	NULL
succinate	NULL
to	NULL
suppress	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

Monolayers	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
before	NULL
challenge	NULL
with	NULL
Listeria	NULL
to	NULL
graded	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
(	NULL
-	NULL
«	NULL
-	NULL
)	NULL
,	NULL
cortisol	NULL
(	NULL
-e-	NULL
)	NULL
,	NULL
or	NULL
hydrocortisone	NULL
succinate	NULL
(	NULL
«	NULL
>	NULL
)	NULL
.	NULL

For	NULL
this	NULL
comparison	NULL
,	NULL
ethanol	NULL
,	NULL
the	NULL
solvent	NULL
for	NULL
cortisol	NULL
and	NULL
dexamethasone	NULL
,	NULL
was	NULL
added	NULL
in	NULL
the	NULL
appropriate	NULL
concentrations	NULL
to	NULL
cultures	NULL
with	NULL
hydrocortisone	NULL
succinate	NULL
,	NULL
which	NULL
was	NULL
directly	NULL
diluted	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
in	NULL
which	NULL
ethanol	NULL
was	NULL
omitted	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mean+SD	NULL
of	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
remaining	NULL
infected	NULL
8	NULL
h	NULL
after	NULL
challenge	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

phages	NULL
from	NULL
normal	NULL
volunteers	NULL
with	NULL
that	NULL
of	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
granulomatous	NULL
disease	NULL
which	NULL
are	NULL
unable	NULL
to	NULL
mount	NULL
a	NULL
respiratory	NULL
burst	NULL
,	NULL
we	NULL
found	NULL
that	NULL
both	NULL
kinds	NULL
of	NULL
cells	NULL
were	NULL
equally	NULL
effective	NULL
in	NULL
inhibiting	NULL
the	NULL
fungus	NULL
and	NULL
equally	NULL
susceptible	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
dexamethasone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
D	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
confirmed	NULL
with	NULL
blood-derived	NULL
macrophages	NULL
from	NULL
two	NULL
additional	NULL
chronic	NULL
granulomatous	NULL
disease	NULL
(	NULL
CGD	NULL
)	NULL
patients	NULL
.	NULL

Exposure	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
from	NULL
a	NULL
second	NULL
individual	NULL
with	NULL
CGD	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
M	NULL
of	NULL
dexamethasone	NULL
for	NULL
36	NULL
h	NULL
increased	NULL
the	NULL
germination	NULL
rate	NULL
of	NULL
ingested	NULL
spores	NULL
4.6+0.4-fold	NULL
(	NULL
mean+SD	NULL
of	NULL
increase	NULL
from	NULL
quadruplicate	NULL
wells	NULL
)	NULL
over	NULL
that	NULL
of	NULL
spores	NULL
ingested	NULL
by	NULL
CGD	NULL
control	NULL
cells	NULL
,	NULL
compared	NULL
with	NULL
an	NULL
increase	NULL
of	NULL
the	NULL
germination	NULL
rate	NULL
of	NULL
5.2+0.3-fold	NULL
for	NULL
spores	NULL
ingested	NULL
by	NULL
cells	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
)	NULL
.	NULL

Cortisol	NULL
in	NULL
a	NULL
concentration	NULL
of	NULL
2.5	NULL
X	NULL
10~°	NULL
mol/liter	NULL
had	NULL
a	NULL
comparable	NULL
effect	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
cells	NULL
from	NULL
a	NULL
third	NULL
individual	NULL
with	NULL
CGD	NULL
with	NULL
a	NULL
4.9+0.2-fold	NULL
increase	NULL
of	NULL
the	NULL
germination	NULL
rate	NULL
after	NULL
36	NULL
h	NULL
exposure	NULL
to	NULL
the	NULL
same	NULL
hormone	NULL
concentration	NULL
(	NULL
compared	NULL
with	NULL
5.2+0.3-fold	NULL
increase	NULL
with	NULL
cells	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
studied	NULL
in	NULL
parallel	NULL
;	NULL
P	NULL
>	NULL
0.05	NULL
for	NULL
all	NULL
comparisons	NULL
between	NULL
CGD	NULL
and	NULL
control	NULL
cells	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
GC	NULL
affect	NULL
the	NULL
antibacterial	NULL
activity	NULL
of	NULL
macrophages	NULL
comparably	NULL
to	NULL
the	NULL
activity	NULL
against	NULL
Aspergillus	NULL
spores	NULL
,	NULL
we	NULL
next	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

Listeria	NULL
monocytogenes	NULL
was	NULL
selected	NULL
because	NULL
previous	NULL
studies	NULL
in	NULL
mice	NULL
indicated	NULL
that	NULL
damage	NULL
to	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
resident	NULL
macrophages	NULL
by	NULL
GC	NULL
is	NULL
a	NULL
critical	NULL
immunosuppressive	NULL
mechanism	NULL
in	NULL
listeriosis	NULL
Glucocorticoid	NULL
Effect	NULL
on	NULL
Macrophages	NULL
-	NULL
1759	NULL
(	NULL
8	NULL
)	NULL
.	NULL

First	NULL
,	NULL
a	NULL
model	NULL
was	NULL
developed	NULL
in	NULL
which	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
could	NULL
be	NULL
assessed	NULL
morphologically	NULL
by	NULL
enumerating	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
harboring	NULL
bacteria	NULL
over	NULL
time	NULL
.	NULL

This	NULL
was	NULL
possible	NULL
since	NULL
normally	NULL
bacteria	NULL
disappeared	NULL
from	NULL
70-80	NULL
%	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
within	NULL
8	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Bacteria	NULL
disappeared	NULL
from	NULL
phagocytes	NULL
by	NULL
destruction	NULL
and	NULL
digestion	NULL
since	NULL
the	NULL
number	NULL
of	NULL
bacteria	NULL
did	NULL
not	NULL
increase	NULL
in	NULL
the	NULL
supernatant	NULL
(	NULL
<	NULL
2	NULL
x	NULL
10°	NULL
bacteria/ml	NULL
at	NULL
each	NULL
time	NULL
point	NULL
)	NULL
.	NULL

There	NULL
was	NULL
also	NULL
no	NULL
selective	NULL
loss	NULL
of	NULL
infected	NULL
cells	NULL
to	NULL
the	NULL
supernatant	NULL
during	NULL
incubation	NULL
because	NULL
cells	NULL
were	NULL
not	NULL
detectable	NULL
in	NULL
cytospin	NULL
preparations	NULL
from	NULL
the	NULL
supernatant	NULL
.	NULL

8	NULL
h	NULL
after	NULL
challenge	NULL
with	NULL
bacteria	NULL
,	NULL
infected	NULL
cells	NULL
were	NULL
randomly	NULL
distributed	NULL
over	NULL
the	NULL
monolayer	NULL
.	NULL

Thereafter	NULL
,	NULL
clusters	NULL
of	NULL
infected	NULL
cells	NULL
arose	NULL
around	NULL
individual	NULL
macrophages	NULL
overwhelmed	NULL
by	NULL
intracellularly	NULL
multiplying	NULL
bacteria	NULL
in	NULL
dexamethasone-treated	NULL
monolayers	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
rapid	NULL
increase	NULL
of	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
harboring	NULL
bacteria	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
remaining	NULL
infected	NULL
after	NULL
an	NULL
incubation	NULL
period	NULL
of	NULL
8	NULL
h	NULL
reflected	NULL
the	NULL
activity	NULL
of	NULL
macrophages	NULL
against	NULL
the	NULL
initial	NULL
inoculum	NULL
,	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
being	NULL
infected	NULL
at	NULL
14	NULL
h	NULL
was	NULL
also	NULL
influenced	NULL
by	NULL
infection	NULL
of	NULL
additional	NULL
cells	NULL
during	NULL
the	NULL
experiment	NULL
in	NULL
dexamethasone-treated	NULL
monolayers	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
all	NULL
subsequent	NULL
experiments	NULL
we	NULL
chose	NULL
an	NULL
incubation	NULL
time	NULL
of	NULL
8	NULL
h	NULL
after	NULL
challenge	NULL
,	NULL
for	NULL
evaluation	NULL
of	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

By	NULL
this	NULL
time	NULL
the	NULL
effects	NULL
of	NULL
regimens	NULL
for	NULL
modulation	NULL
of	NULL
macrophage	NULL
function	NULL
(	NULL
studied	NULL
in	NULL
detail	NULL
below	NULL
)	NULL
appeared	NULL
to	NULL
be	NULL
fully	NULL
developed	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

To	NULL
prevent	NULL
continuous	NULL
infection	NULL
of	NULL
macrophages	NULL
by	NULL
extracellularly	NULL
multiplying	NULL
bacteria	NULL
during	NULL
incubation	NULL
,	NULL
we	NULL
routinely	NULL
added	NULL
a	NULL
bacteriostatic	NULL
concentration	NULL
of	NULL
tobramycin	NULL
(	NULL
1.2	NULL
ug/ml	NULL
)	NULL
to	NULL
the	NULL
cultures	NULL
after	NULL
we	NULL
washed	NULL
off	NULL
bacteria	NULL
not	NULL
ingested	NULL
by	NULL
cells	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
antibiotic	NULL
distorted	NULL
the	NULL
results	NULL
of	NULL
a	NULL
comparison	NULL
of	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
differently	NULL
treated	NULL
macrophage	NULL
preparations	NULL
was	NULL
excluded	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
was	NULL
dose-dependent	NULL
and	NULL
inhibited	NULL
by	NULL
progesterone	NULL
in	NULL
a	NULL
manner	NULL
comparable	NULL
to	NULL
that	NULL
in	NULL
the	NULL
Aspergillus	NULL
model	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
)	NULL
.	NULL

As	NULL
with	NULL
Aspergillus	NULL
,	NULL
cortisol	NULL
seemed	NULL
to	NULL
be	NULL
about	NULL
10	NULL
times	NULL
less	NULL
potent	NULL
than	NULL
dexamethasone	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
potency	NULL
of	NULL
hydrocortisone	NULL
succinate	NULL
was	NULL
investigated	NULL
in	NULL
the	NULL
Listeria	NULL
model	NULL
to	NULL
permit	NULL
comparison	NULL
with	NULL
previous	NULL
reports	NULL
in	NULL
which	NULL
this	NULL
steroid	NULL
was	NULL
studied	NULL
(	NULL
9	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Not	NULL
unexpectedly	NULL
,	NULL
cortisol	NULL
was	NULL
more	NULL
potent	NULL
compared	NULL
with	NULL
the	NULL
synthetic	NULL
derivative	NULL
because	NULL
esterification	NULL
of	NULL
the	NULL
hydroxy	NULL
group	NULL
of	NULL
cortisol	NULL
at	NULL
position	NULL
C21	NULL
reduces	NULL
affinity	NULL
to	NULL
the	NULL
GC	NULL
receptor	NULL
(	NULL
23	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
observed	NULL
10-fold	NULL
difference	NULL
in	NULL
the	NULL
potency	NULL
of	NULL
the	NULL
two	NULL
hydrocortisone	NULL
compounds	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
could	NULL
not	NULL
account	NULL
for	NULL
the	NULL
175-fold	NULL
difference	NULL
between	NULL
the	NULL
16	NULL
ug/ml	NULL
of	NULL
hydrocortisone	NULL
succinate	NULL
needed	NULL
for	NULL
suppression	NULL
of	NULL
macrophage	NULL
antimicrobial	NULL
activity	NULL
in	NULL
one	NULL
of	NULL
the	NULL
cited	NULL
studies	NULL
(	NULL
11	NULL
)	NULL
and	NULL
the	NULL
present	NULL
finding	NULL
that	NULL
90	NULL
ng	NULL
of	NULL
cortisol	NULL
fully	NULL
suppressed	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
time	NULL
course	NULL
of	NULL
the	NULL
GC	NULL
effect	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
again	NULL
showed	NULL
that	NULL
prolonged	NULL
incubation	NULL
of	NULL
macrophages	NULL
with	NULL
GC	NULL
was	NULL
necessary	NULL
to	NULL
achieve	NULL
a	NULL
suppressive	NULL
effect	NULL
at	NULL
pharmacological	NULL
hormone	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
.	NULL

Because	NULL
macrophages	NULL
were	NULL
only	NULL
exposed	NULL
for	NULL
a	NULL
few	NULL
hours	NULL
to	NULL
GC	NULL
in	NULL
studies	NULL
with	NULL
suprapharmacological	NULL
concentrations	NULL
of	NULL
hydrocortisone	NULL
succinate	NULL
(	NULL
11	NULL
)	NULL
,	NULL
differences	NULL
in	NULL
the	NULL
duration	NULL
of	NULL
GC	NULL
exposure	NULL
appear	NULL
even	NULL
more	NULL
important	NULL
than	NULL
the	NULL
kind	NULL
of	NULL
hydrocortisone	NULL
used	NULL
to	NULL
explain	NULL
the	NULL
impressive	NULL
difference	NULL
between	NULL
GC	NULL
concentrations	NULL
required	NULL
for	NULL
damage	NULL
of	NULL
macrophage	NULL
activity	NULL
in	NULL
this	NULL
and	NULL
the	NULL
cited	NULL
study	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
Listeria	NULL
system	NULL
apparently	NULL
required	NULL
an	NULL
additional	NULL
12	NULL
h	NULL
to	NULL
develop	NULL
a	NULL
full	NULL
dexamethasone	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
fungus	NULL
system	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
,	NULL
however	NULL
,	NULL
was	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
different	NULL
assay	NULL
techniques	NULL
used	NULL
.	NULL

While	NULL
germination	NULL
of	NULL
Aspergillus	NULL
spores	NULL
was	NULL
quantitated	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
,	NULL
cells	NULL
infected	NULL
with	NULL
Listeria	NULL
were	NULL
enumerated	NULL
8	NULL
h	NULL
after	NULL
infection	NULL
of	NULL
macrophages	NULL
,	NULL
allowing	NULL
for	NULL
a	NULL
more	NULL
extended	NULL
contact	NULL
with	NULL
the	NULL
GC	NULL
in	NULL
experiments	NULL
involving	NULL
spores	NULL
.	NULL

20	NULL
%	NULL
40	NULL
%	NULL
60	NULL
%	NULL
80	NULL
%	NULL
Figure	NULL
5	NULL
.	NULL

Effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antifungal	NULL
and	NULL
.	NULL

a	NULL
M	NULL
antibacterial	NULL
activity	NULL
of	NULL
blood-derived	NULL
macrophages	NULL
after	NULL
Control	NULL
-	NULL
A	NULL
in	NULL
vitro	NULL
culture	NULL
for	NULL
4	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
proliferating	NULL
Dex	NULL
d	NULL
2-4	NULL
sxs	NULL
8	NULL
sss	NULL
sA	NULL
lymphocytes	NULL
.	NULL

(	NULL
4	NULL
)	NULL
percentage	NULL
of	NULL
macrophages	NULL
infected	NULL
with	NULL
L.	NULL
monocytogenes	NULL
8	NULL
h	NULL
after	NULL
challenge	NULL
;	NULL
the	NULL
infection	NULL
rate	NULL
Lyc	NULL
+	NULL
Dex	NULL
d2-	NULL
4	NULL
-	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
was	NULL
91-96	NULL
%	NULL
with	NULL
0-amrs	NULL
}	NULL
8	NULL
bacteria/cell	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Germination	NULL
rate	NULL
of	NULL
Aspergillus	NULL
spores	NULL
PPD	NULL
+Dex	NULL
d2-4	NULL
PPD	NULL
NNY	NULL
%	NULL
Cells	NULL
Infected	NULL
Lyc+	NULL
PPD+	NULL
Dex	NULL
d2-4	NULL
Lyc	NULL
+PPD+	NULL
Dex	NULL
do-4	NULL
Y-	NULL
IF	NULL
+	NULL
Dex	NULL
d2-4	NULL
;	NULL
F	NULL
Control	NULL
Dex	NULL
d	NULL
2-4	NULL
LEE	NULL
me	NULL
a	NULL
a	NULL
a	NULL
ome	NULL
a	NULL
am	NULL
o	NULL
m	NULL
rim	NULL
s	NULL
aoe	NULL
t	NULL
a	NULL
m	NULL
am	NULL
c	NULL
om	NULL
a	NULL
a	NULL
a	NULL
o	NULL
a	NULL
a	NULL
a	NULL
n	NULL
a	NULL
a	NULL
a	NULL
a	NULL
t	NULL
t	NULL
t	NULL
+-Lyc	NULL
+	NULL
PPD	NULL
Lyc	NULL
+	NULL
PPD+Dex	NULL
d2-4	NULL
y-	NULL
1F	NULL
+Dex	NULL
42-4	NULL
MWH	NULL
%	NULL
cells	NULL
with	NULL
>	NULL
10	NULL
Listeria	NULL
IMID	NULL
Germination	NULL
Rate	NULL
(	NULL
%	NULL
)	NULL
E0	NULL
24	NULL
h	NULL
after	NULL
phagocytosis	NULL
by	NULL
macrophages	NULL
.	NULL

Control	NULL
,	NULL
monolayers	NULL
cultured	NULL
for	NULL
4	NULL
d	NULL
before	NULL
challenge	NULL
in	NULL
control	NULL
medium	NULL
.	NULL

Dex	NULL
d2-4	NULL
,	NULL
monolayers	NULL
cultured	NULL
for	NULL
2	NULL
d	NULL
in	NULL
control	NULL
medium	NULL
and	NULL
then	NULL
for	NULL
2	NULL
d	NULL
before	NULL
challenge	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
dexamethasone	NULL
.	NULL

Lyc	NULL
+	NULL
Dex	NULL
d2-4	NULL
,	NULL
monolayers	NULL
of	NULL
macrophages	NULL
to	NULL
which	NULL
lymphocytes	NULL
were	NULL
replenished	NULL
were	NULL
cultured	NULL
for	NULL
2	NULL
d	NULL
in	NULL
control	NULL
medium	NULL
and	NULL
then	NULL
for	NULL
2	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
.	NULL

PPD	NULL
+	NULL
Dex	NULL
d2-4	NULL
,	NULL
monolayers	NULL
cultured	NULL
for	NULL
2	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PPD	NULL
and	NULL
then	NULL
for	NULL
2	NULL
d	NULL
before	NULL
challenge	NULL
with	NULL
PPD	NULL
and	NULL
dexamethasone	NULL
.	NULL

Lyc	NULL
+	NULL
PPD	NULL
,	NULL
lymphocyte-replenished	NULL
monolayers	NULL
cultured	NULL
for	NULL
4	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PPD	NULL
.	NULL

Lyc	NULL
+	NULL
PPD	NULL
+	NULL
Dex	NULL
d2-4	NULL
,	NULL
lymphocyte-replenished	NULL
monolayers	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PPD	NULL
for	NULL
2	NULL
d	NULL
and	NULL
then	NULL
for	NULL
2	NULL
d	NULL
before	NULL
challenge	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
dexamethasone	NULL
and	NULL
PPD	NULL
.	NULL

Lyc	NULL
+	NULL
PPD	NULL
+	NULL
Dex	NULL
d0-4	NULL
,	NULL
to	NULL
lymphocyte-replenished	NULL
monolayers	NULL
dexamethasone	NULL
was	NULL
added	NULL
and	NULL
2	NULL
h	NULL
later	NULL
,	NULL
PPD	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
cultured	NULL
with	NULL
Ie	NULL
m	NULL
m	NULL
a	NULL
ame	NULL
m	NULL
a	NULL
m	NULL
a	NULL
ag	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
m	NULL
a	NULL
me	NULL
a	NULL
o	NULL
o	NULL
a	NULL
o	NULL
o	NULL
a	NULL
a	NULL
m	NULL
a	NULL
t	NULL
a	NULL
t	NULL
a	NULL
t	NULL
a	NULL
d	NULL
t	NULL
these	NULL
supplements	NULL
for	NULL
4	NULL
d	NULL
before	NULL
challenge	NULL
.	NULL

y-IF	NULL
+	NULL
Dex	NULL
d2-4	NULL
,	NULL
monolayers	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
y-IFN	NULL
and	NULL
dexamethasone	NULL
for	NULL
4	NULL
d	NULL
before	NULL
challenge	NULL
.	NULL

The	NULL
concentrations	NULL
were	NULL
:	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
M	NULL
for	NULL
dexamethasone	NULL
,	NULL
50	NULL
ug/ml	NULL
for	NULL
PPD	NULL
,	NULL
48	NULL
U/ml	NULL
for	NULL
y-IFN	NULL
,	NULL
and	NULL
2	NULL
X	NULL
10°	NULL
autologous	NULL
lymphocytes	NULL
per	NULL
milliliter	NULL
from	NULL
a	NULL
PPD-sensitized	NULL
donor	NULL
.	NULL

Soluble	NULL
additives	NULL
were	NULL
replaced	NULL
with	NULL
each	NULL
medium	NULL
change	NULL
(	NULL
day	NULL
0	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Each	NULL
bar	NULL
represents	NULL
the	NULL
mean+SD	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
representative	NULL
exberiment	NULL
out	NULL
of	NULL
three	NULL
.	NULL

1760	NULL
-	NULL
A.	NULL
Schaffner	NULL
Influence	NULL
of	NULL
macrophage	NULL
activation	NULL
by	NULL
proliferating	NULL
lymphocytes	NULL
or	NULL
y-interferon	NULL
on	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
macrophages	NULL
was	NULL
studied	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
proliferating	NULL
lymphocytes	NULL
stimulated	NULL
either	NULL
by	NULL
a	NULL
recall	NULL
antigen	NULL
or	NULL
by	NULL
Con	NULL
A	NULL
.	NULL

When	NULL
macrophages	NULL
and	NULL
stimulated	NULL
lymphocytes	NULL
were	NULL
cocultured	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
exposed	NULL
to	NULL
dexamethasone	NULL
,	NULL
the	NULL
GC	NULL
could	NULL
no	NULL
longer	NULL
suppress	NULL
antilisterial	NULL
activity	NULL
of	NULL
the	NULL
phagocytes	NULL
below	NULL
that	NULL
of	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
when	NULL
the	NULL
GC	NULL
was	NULL
added	NULL
to	NULL
monolayers	NULL
cocultured	NULL
with	NULL
PPD-sensitized	NULL
lymphocytes	NULL
2	NULL
h	NULL
before	NULL
the	NULL
stimulating	NULL
antigen	NULL
,	NULL
macrophages	NULL
cultured	NULL
for	NULL
4	NULL
d	NULL
under	NULL
these	NULL
conditions	NULL
before	NULL
challenge	NULL
,	NULL
still	NULL
acquired	NULL
GC	NULL
resistance	NULL
and	NULL
eliminated	NULL
bacteria	NULL
much	NULL
more	NULL
efficiently	NULL
than	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
macrophage	NULL
activation	NULL
occurred	NULL
in	NULL
spite	NULL
of	NULL
a	NULL
suppressed	NULL
(	NULL
but	NULL
not	NULL
completely	NULL
abolished	NULL
)	NULL
proliferation	NULL
of	NULL
lymphoblasts	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
GC	NULL
(	NULL
compared	NULL
with	NULL
control	NULL
wells	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
in	NULL
several	NULL
similar	NULL
experiments	NULL
the	NULL
effects	NULL
of	NULL
PPD-sensitized	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PPD	NULL
were	NULL
compared	NULL
with	NULL
the	NULL
effects	NULL
of	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
Con	NULL
A	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
y-IFN	NULL
has	NULL
been	NULL
recognized	NULL
as	NULL
an	NULL
important	NULL
macro-phage-activating	NULL
factor	NULL
produced	NULL
by	NULL
T	NULL
lymphocytes	NULL
(	NULL
24-26	NULL
)	NULL
,	NULL
we	NULL
did	NULL
a	NULL
series	NULL
of	NULL
experiments	NULL
in	NULL
which	NULL
human	NULL
recombinant	NULL
y-IFN	NULL
replaced	NULL
proliferating	NULL
lymphocytes	NULL
.	NULL

y-IFN	NULL
could	NULL
replace	NULL
proliferating	NULL
lymphocytes	NULL
in	NULL
rendering	NULL
macrophages	NULL
completely	NULL
resistant	NULL
to	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

Furthermore	NULL
,	NULL
dexamethasone	NULL
at	NULL
a	NULL
concentration	NULL
100	NULL
times	NULL
higher	NULL
than	NULL
that	NULL
required	NULL
to	NULL
fully	NULL
suppress	NULL
antilisterial	NULL
activity	NULL
of	NULL
``	NULL
resting	NULL
``	NULL
macrophages	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
macrophage	NULL
activation	NULL
by	NULL
y-IFN	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
.	NULL

Challenge	NULL
of	NULL
macrophages	NULL
with	NULL
higher	NULL
numbers	NULL
of	NULL
bacteria	NULL
resulted	NULL
in	NULL
heavy	NULL
infection	NULL
of	NULL
individual	NULL
cells	NULL
during	NULL
phagocytosis	NULL
,	NULL
and	NULL
under	NULL
these	NULL
conditions	NULL
even	NULL
cells	NULL
not	NULL
exposed	NULL
to	NULL
GC	NULL
had	NULL
difficulties	NULL
controlling	NULL
intracellular	NULL
bacteria	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
heavily	NULL
bacteria-laden	NULL
macrophages	NULL
activated	NULL
by	NULL
y-IFN	NULL
destroyed	NULL
all	NULL
intracellular	NULL
bacteria	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
dexamethasone	NULL
also	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
activation	NULL
except	NULL
at	NULL
a	NULL
very	NULL
low	NULL
y-IFN	NULL
concentration	NULL
below	NULL
a	NULL
fully	NULL
activating	NULL
dose	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

When	NULL
the	NULL
time	NULL
course	NULL
of	NULL
reversion	NULL
of	NULL
the	NULL
dexamethasone	NULL
effect	NULL
on	NULL
macrophages	NULL
by	NULL
y-IFN	NULL
was	NULL
studied	NULL
,	NULL
it	NULL
became	NULL
apparent	NULL
that	NULL
y-IFN	NULL
affected	NULL
macrophage	NULL
function	NULL
much	NULL
more	NULL
rapidly	NULL
than	NULL
dexamethasone	NULL
,	NULL
because	NULL
addition	NULL
of	NULL
y-IFN	NULL
only	NULL
2	NULL
h	NULL
before	NULL
phagocytosis	NULL
resulted	NULL
in	NULL
a	NULL
nearly	NULL
complete	NULL
restitution	NULL
of	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
GC-treated	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
compared	NULL
with	NULL
36	NULL
h	NULL
of	NULL
exposure	NULL
required	NULL
to	NULL
produce	NULL
dexamethasone	NULL
damage	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
experiments	NULL
confirmed	NULL
that	NULL
even	NULL
after	NULL
prolonged	NULL
exposure	NULL
of	NULL
macrophages	NULL
to	NULL
therapeutic	NULL
dexamethasone	NULL
levels	NULL
,	NULL
the	NULL
phagocytes	NULL
still	NULL
responded	NULL
to	NULL
y-IFN	NULL
by	NULL
rapid	NULL
restoration	NULL
of	NULL
the	NULL
antilisterial	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
observations	NULL
with	NULL
Listeria	NULL
,	NULL
y-IFN	NULL
in	NULL
concentrations	NULL
of	NULL
10-100	NULL
U/ml	NULL
and	NULL
proliferating	NULL
lymphocytes	NULL
neither	NULL
prevented	NULL
nor	NULL
reverted	NULL
the	NULL
deleterious	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
blood-derived	NULL
or	NULL
alveolar	NULL
macrophages	NULL
against	NULL
Aspergillus	NULL
spores	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
higher	NULL
y-IFN	NULL
concentrations	NULL
up	NULL
to	NULL
10°	NULL
U/ml	NULL
were	NULL
without	NULL
effect	NULL
on	NULL
the	NULL
antifungal	NULL
activity	NULL
of	NULL
macrophages	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
y-IFN	NULL
corrects	NULL
only	NULL
for	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
GC	NULL
on	NULL
macrophage	NULL
activity	NULL
for	NULL
certain	NULL
microorganisms	NULL
was	NULL
confirmed	NULL
with	NULL
Salmonella	NULL
typhimurium	NULL
and	NULL
Nocardia	NULL
asteroides	NULL
.	NULL

These	NULL
organisms	NULL
were	NULL
selected	NULL
because	NULL
of	NULL
their	NULL
opportunism	NULL
in	NULL
patients	NULL
undergoing	NULL
glucocorticoid	NULL
therapy	NULL
,	NULL
because	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
parasitize	NULL
macrophages	NULL
,	NULL
and	NULL
because	NULL
of	NULL
possible	NULL
differences	NULL
in	NULL
their	NULL
susceptibility	NULL
to	NULL
killing	NULL
by	NULL
phagocytes	NULL
.	NULL

While	NULL
y-IFN	NULL
cor-	NULL
%	NULL
CELLS	NULL
INFECTED	NULL
&	NULL
0	NULL
101	NULL
1	NULL
1	NULL
1966	NULL
16	NULL
``	NULL
106°	NULL
199	NULL
0	NULL
DEXAMETHASONE	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
:	NULL
2.5	NULL
)	NULL
Figure	NULL
6	NULL
A	NULL
.	NULL

Prevention	NULL
by	NULL
y-IFN	NULL
of	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
.	NULL

Blood-derived	NULL
macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
to	NULL
graded	NULL
doses	NULL
of	NULL
dexamethasone	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
a	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
e	NULL
)	NULL
of	NULL
20	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
.	NULL

Immediately	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
61	NULL
%	NULL
of	NULL
cells	NULL
were	NULL
infected	NULL
(	NULL
0-4	NULL
bacteria/cell	NULL
)	NULL
.	NULL

Mean+SD	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
remaining	NULL
infected	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

70	NULL
B	NULL
I	NULL
V	NULL
a	NULL
501	NULL
u	NULL
o	NULL
Lu	NULL
lie	NULL
€	NULL
t	NULL
P	NULL
a	NULL
so	NULL
o	NULL
a	NULL
10	NULL
ﬁ	NULL
36	NULL
24	NULL
12	NULL
FY	NULL
i	NULL
none	NULL
START	NULL
OF	NULL
Y-	NULL
INTERFERON	NULL
EXPOSURE	NULL
(	NULL
hours	NULL
before	NULL
challenge	NULL
}	NULL
Figure	NULL
6	NULL
B	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
the	NULL
y-IFN	NULL
effect	NULL
on	NULL
dexamethasone	NULL
damaged	NULL
macrophages	NULL
in	NULL
the	NULL
Listeria	NULL
system	NULL
.	NULL

To	NULL
macrophages	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
to	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
M	NULL
of	NULL
dexamethasone	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
were	NULL
added	NULL
at	NULL
various	NULL
time	NULL
intervals	NULL
before	NULL
challenge	NULL
(	NULL
arrow	NULL
)	NULL
or	NULL
immediately	NULL
after	NULL
challenge	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
mean+SD	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
infected	NULL
with	NULL
Listeria	NULL
8	NULL
h	NULL
after	NULL
phagocytosis	NULL
from	NULL
quadruplicate	NULL
wells	NULL
of	NULL
an	NULL
independent	NULL
experiment	NULL
.	NULL

The	NULL
infection	NULL
rate	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
53+3	NULL
%	NULL
and	NULL
51+2	NULL
%	NULL
(	NULL
mean+SD	NULL
)	NULL
immediately	NULL
after	NULL
removal	NULL
of	NULL
noningested	NULL
bacteria	NULL
with	NULL
no	NULL
significant	NULL
difference	NULL
for	NULL
cells	NULL
exposed	NULL
for	NULL
various	NULL
time	NULL
periods	NULL
to	NULL
y-IFN	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
macrophages	NULL
exposed	NULL
neither	NULL
to	NULL
y-IFN	NULL
nor	NULL
to	NULL
dexamethasone	NULL
remaining	NULL
infected	NULL
with	NULL
bacteria	NULL
8	NULL
h	NULL
after	NULL
phagocytosis	NULL
was	NULL
6.5+2	NULL
%	NULL
and	NULL
7+2	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

Glucocorticoid	NULL
Effect	NULL
on	NULL
Macrophages	NULL
-	NULL
1761	NULL
A	NULL
B	NULL
C	NULL
g	NULL
``	NULL
J	NULL
g	NULL
I	NULL
gControl	NULL
+	NULL
J	NULL
+	NULL
l	NULL
'	NULL
6	NULL
l	NULL
é	NULL
?	NULL

?	NULL

?	NULL

éDexa	NULL
a	NULL
;	NULL
7	NULL
#	NULL
pag	NULL
bE	NULL
G	NULL
2	NULL
3	NULL
J	NULL
J	NULL
£11151	NULL
[	NULL
lii	NULL
lilig	NULL
}	NULL
$	NULL
9	NULL
¥	NULL
%	NULL
|	NULL
%	NULL
%	NULL
Z	NULL
-|	NULL
&	NULL
§	NULL
&	NULL
%	NULL
%	NULL
%	NULL
Z	NULL
#	NULL
8	NULL
2	NULL
3	NULL
&	NULL
J|	NULL
&	NULL
&	NULL
E/S	NULL
}	NULL
|	NULL
I|	NULL
2	NULL
§	NULL
J	NULL
J	NULL
9	NULL
3	NULL
2	NULL
+	NULL
A	NULL
#	NULL
§	NULL
Z	NULL
Alli	NULL
Di	NULL
15	NULL
{	NULL
t	NULL
12	NULL
»	NULL
2	NULL
a	NULL
a	NULL
#	NULL
J	NULL
g	NULL
2	NULL
2	NULL
$	NULL
,	NULL
M	NULL
2	NULL
gig	NULL
;	NULL
1U	NULL
-	NULL
104	NULL
1000	NULL
0	NULL
-	NULL
20U	NULL
200U	NULL
0	NULL
_	NULL
10	NULL
10U	NULL
100U	NULL
CONCENTRATION	NULL
OF	NULL
Y-	NULL
INTERFERON	NULL
Figure	NULL
7	NULL
.	NULL

Failure	NULL
of	NULL
y-IFN	NULL
to	NULL
modulate	NULL
the	NULL
activity	NULL
of	NULL
dexamethasone-treated	NULL
or	NULL
normal	NULL
macrophages	NULL
against	NULL
spores	NULL
from	NULL
A4	NULL
.	NULL

fumigatus	NULL
.	NULL

Macrophages	NULL
were	NULL
cultured	NULL
for	NULL
36	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
Dexa	NULL
)	NULL
or	NULL
abserice	NULL
(	NULL
Control	NULL
)	NULL
of	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
and	NULL
were	NULL
simultaneously	NULL
exposed	NULL
to	NULL
graded	NULL
doses	NULL
of	NULL
y-IFN	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Germination	NULL
rate	NULL
of	NULL
spores	NULL
ingested	NULL
by	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Germination	NULL
rate	NULL
of	NULL
spores	NULL
ingested	NULL
by	NULL
alveolar	NULL
macrophages	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Percent	NULL
blood-derived	NULL
macrophages	NULL
remaining	NULL
infected	NULL
8	NULL
h	NULL
after	NULL
ingestion	NULL
of	NULL
L.	NULL
monocytogenes	NULL
(	NULL
91-96	NULL
%	NULL
cells	NULL
initially	NULL
infected	NULL
with	NULL
0-10	NULL
bacteria	NULL
)	NULL
.	NULL

Results	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
experiment	NULL
with	NULL
alveolar	NULL
macrophages	NULL
and	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
with	NULL
blood-derived	NULL
macrophages	NULL
.	NULL

rected	NULL
for	NULL
the	NULL
glucocorticoid	NULL
damage	NULL
in	NULL
the	NULL
Salmonella	NULL
model	NULL
,	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
did	NULL
not	NULL
prevent	NULL
glucocorticoid	NULL
damage	NULL
in	NULL
the	NULL
Nocardia	NULL
model	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
experiment	NULL
was	NULL
repeated	NULL
with	NULL
even	NULL
higher	NULL
concentrations	NULL
of	NULL
y-IFN	NULL
.	NULL

Thus	NULL
,	NULL
y-IFN	NULL
in	NULL
concentrations	NULL
up	NULL
to	NULL
120	NULL
U/ml	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
completely	NULL
suppressed	NULL
elimination	NULL
of	NULL
Nocardia	NULL
but	NULL
again	NULL
restored	NULL
in	NULL
parallel	NULL
studies	NULL
with	NULL
cells	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
elimination	NULL
of	NULL
Salmonella	NULL
by	NULL
dexamethasone-treated	NULL
cells	NULL
to	NULL
a	NULL
rate	NULL
comparable	NULL
to	NULL
that	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
characterizes	NULL
in	NULL
vitro	NULL
a	NULL
deleterious	NULL
effect	NULL
of	NULL
therapeutic	NULL
glucocorticoid	NULL
concentrations	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
macrophages	NULL
to	NULL
kill	NULL
ingested	NULL
microorganisms	NULL
.	NULL

The	NULL
results	NULL
prove	NULL
in	NULL
pure	NULL
in	NULL
vitro	NULL
systems	NULL
direct	NULL
damage	NULL
by	NULL
pharmacological	NULL
glucocorticoid	NULL
levels	NULL
to	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
,	NULL
an	NULL
effect	NULL
found	NULL
to	NULL
be	NULL
critical	NULL
in	NULL
several	NULL
models	NULL
of	NULL
opportunistic	NULL
infections	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
15	NULL
)	NULL
.	NULL

When	NULL
macrophages	NULL
were	NULL
exposed	NULL
for	NULL
24-36	NULL
h	NULL
to	NULL
GC	NULL
,	NULL
the	NULL
antifungal	NULL
and	NULL
antibacterial	NULL
activity	NULL
of	NULL
the	NULL
phagocytes	NULL
was	NULL
fully	NULL
suppressed	NULL
by	NULL
as	NULL
little	NULL
as	NULL
10	NULL
ng/ml	NULL
of	NULL
dexamethasone	NULL
and	NULL
100	NULL
ng/ml	NULL
of	NULL
cortisol	NULL
with	NULL
no	NULL
greater	NULL
effect	NULL
of	NULL
GC	NULL
concentrations	NULL
up	NULL
to	NULL
10	NULL
ug/ml	NULL
.	NULL

These	NULL
GC	NULL
concentrations	NULL
are	NULL
clearly	NULL
in	NULL
the	NULL
therapeutic	NULL
range	NULL
.	NULL

On	NULL
one	NULL
hand	NULL
,	NULL
physiological	NULL
plasma	NULL
cortisol	NULL
levels	NULL
range	NULL
from	NULL
8	NULL
to	NULL
220	NULL
ng/ml	NULL
during	NULL
the	NULL
diurnal	NULL
cycle	NULL
(	NULL
27	NULL
)	NULL
with	NULL
a	NULL
1782	NULL
-	NULL
A.	NULL
Schaffner	NULL
biologically	NULL
available	NULL
(	NULL
14	NULL
)	NULL
concentration	NULL
of	NULL
free	NULL
cortisol	NULL
of	NULL
0.8-28	NULL
ng/ml	NULL
(	NULL
27	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
GC	NULL
therapy	NULL
results	NULL
in	NULL
sustained	NULL
plasma	NULL
drug	NULL
levels	NULL
of	NULL
1-2	NULL
ug/ml	NULL
with	NULL
as	NULL
much	NULL
as	NULL
100	NULL
to	NULL
500	NULL
ng	NULL
unbound	NULL
hormone	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Suppression	NULL
of	NULL
the	NULL
antimicrobial	NULL
activity	NULL
appeared	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
high-affinity	NULL
GC-receptors	NULL
of	NULL
macrophages	NULL
(	NULL
20	NULL
)	NULL
not	NULL
only	NULL
because	NULL
of	NULL
the	NULL
very	NULL
low	NULL
GC	NULL
concentrations	NULL
required	NULL
for	NULL
a	NULL
fully	NULL
suppressive	NULL
effect	NULL
but	NULL
also	NULL
because	NULL
an	NULL
excess	NULL
of	NULL
progesterone	NULL
,	NULL
an	NULL
antagonist	NULL
of	NULL
GC	NULL
at	NULL
the	NULL
receptor	NULL
(	NULL
17	NULL
,	NULL
20	NULL
,	NULL
22	NULL
)	NULL
,	NULL
suppressed	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
previous	NULL
studies	NULL
(	NULL
9	NULL
,	NULL
11	NULL
)	NULL
to	NULL
confirm	NULL
a	NULL
direct	NULL
effect	NULL
of	NULL
therapeutic	NULL
GC	NULL
concentrations	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
in	NULL
vitro	NULL
might	NULL
in	NULL
part	NULL
reflect	NULL
the	NULL
short	NULL
duration	NULL
of	NULL
these	NULL
experiments	NULL
precluding	NULL
an	NULL
expression	NULL
of	NULL
receptor-mediated	NULL
effects	NULL
of	NULL
steroids	NULL
that	NULL
involve	NULL
synthesis	NULL
of	NULL
messenger	NULL
RNA	NULL
and	NULL
proteins	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
use	NULL
of	NULL
synthetic	NULL
steroids	NULL
might	NULL
have	NULL
influenced	NULL
the	NULL
glucocorticoid	NULL
concentration	NULL
required	NULL
for	NULL
a	NULL
suppression	NULL
of	NULL
antimicrobial	NULL
activity	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
hydrocortisone	NULL
succinate	NULL
,	NULL
which	NULL
was	NULL
used	NULL
by	NULL
some	NULL
investigators	NULL
(	NULL
9	NULL
,	NULL
11	NULL
)	NULL
,	NULL
was	NULL
in	NULL
our	NULL
hands	NULL
about	NULL
10	NULL
times	NULL
less	NULL
potent	NULL
than	NULL
cortisol	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
kind	NULL
of	NULL
microorganism	NULL
studied	NULL
by	NULL
different	NULL
authors	NULL
also	NULL
has	NULL
to	NULL
be	NULL
considered	NULL
to	NULL
explain	NULL
disparate	NULL
results	NULL
.	NULL

Thus	NULL
,	NULL
Nash	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
cortisol	NULL
on	NULL
the	NULL
anti-Legionella	NULL
activity	NULL
of	NULL
human	NULL
blood-derived	NULL
and	NULL
alveolar	NULL
macrophages	NULL
.	NULL

In	NULL
this	NULL
system	NULL
``	NULL
resting	NULL
``	NULL
mononuclear	NULL
phagocytes	NULL
do	NULL
not	NULL
display	NULL
anti-Legionella	NULL
activity	NULL
;	NULL
rather	NULL
,	NULL
the	NULL
phagocytes	NULL
are	NULL
required	NULL
to	NULL
support	NULL
bacterial	NULL
growth	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
not	NULL
surprising	NULL
that	NULL
no	NULL
suppressive	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
resting	NULL
macrophages	NULL
was	NULL
noted	NULL
in	NULL
this	NULL
model	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
macrophages	NULL
had	NULL
to	NULL
be	NULL
exposed	NULL
to	NULL
GC	NULL
for	NULL
at	NULL
least	NULL
24	NULL
h	NULL
before	NULL
being	NULL
functionally	NULL
affected	NULL
raises	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
the	NULL
steroid	NULL
merely	NULL
interfered	NULL
with	NULL
a	NULL
non-physiologic	NULL
process	NULL
of	NULL
in	NULL
vitro	NULL
differentiation	NULL
or	NULL
in	NULL
vitro	NULL
functional	NULL
modulation	NULL
during	NULL
culture	NULL
.	NULL

The	NULL
findings	NULL
that	NULL
alveolar	NULL
macrophages	NULL
are	NULL
as	NULL
susceptible	NULL
to	NULL
corticosteroids	NULL
as	NULL
blood-de-	NULL
N.asteroides	NULL
S.	NULL
typhimurium	NULL
604	NULL
507	NULL
40	NULL
307	NULL
%	NULL
CELLS	NULL
INFECTED	NULL
0	NULL
4	NULL
8	NULL
_	NULL
0	NULL
4	NULL
HOURS	NULL
AFTER	NULL
PHaAGgocyTOSsis	NULL
wl	NULL
Figure	NULL
8	NULL
.	NULL

Confirmation	NULL
that	NULL
y-IFN	NULL
corrects	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
only	NULL
for	NULL
certain	NULL
pathogens	NULL
.	NULL

Blood-derived	NULL
macrophages	NULL
were	NULL
exposed	NULL
for	NULL
36	NULL
h	NULL
before	NULL
challenge	NULL
with	NULL
Nocardia	NULL
asteroides	NULL
or	NULL
Salmonella	NULL
typhimurium	NULL
to	NULL
2.5	NULL
X	NULL
107	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
(	NULL
#	NULL
)	NULL
,	NULL
2.5	NULL
X	NULL
10~	NULL
'	NULL
mol/liter	NULL
of	NULL
dexamethasone	NULL
combined	NULL
with	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
or	NULL
48	NULL
U/ml	NULL
of	NULL
y-IFN	NULL
(	NULL
a	NULL
)	NULL
;	NULL
(	NULL
e	NULL
)	NULL
,	NULL
untreated	NULL
control	NULL
cells	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
mean+SD	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
infected	NULL
from	NULL
quadruplicate	NULL
wells	NULL
from	NULL
one	NULL
of	NULL
two	NULL
comparable	NULL
experiments	NULL
.	NULL

rived	NULL
macrophages	NULL
,	NULL
that	NULL
blood	NULL
monocytes	NULL
and	NULL
alveolar	NULL
macrophages	NULL
have	NULL
the	NULL
same	NULL
activity	NULL
against	NULL
Aspergil/us	NULL
whether	NULL
challenged	NULL
with	NULL
the	NULL
fungus	NULL
at	NULL
the	NULL
beginning	NULL
of	NULL
in	NULL
vitro	NULL
culture	NULL
or	NULL
2	NULL
d	NULL
later	NULL
,	NULL
and	NULL
finally	NULL
that	NULL
phagocytes	NULL
cultured	NULL
in	NULL
vitro	NULL
for	NULL
2	NULL
d	NULL
before	NULL
GC	NULL
exposure	NULL
remain	NULL
equally	NULL
dexamethasone-susceptible	NULL
,	NULL
are	NULL
against	NULL
these	NULL
possibilities	NULL
.	NULL

Likewise	NULL
,	NULL
damage	NULL
to	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
from	NULL
laboratory	NULL
animals	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
15	NULL
)	NULL
and	NULL
humans	NULL
(	NULL
29	NULL
)	NULL
has	NULL
also	NULL
only	NULL
been	NULL
shown	NULL
after	NULL
GC	NULL
administration	NULL
for	NULL
more	NULL
than	NULL
24	NULL
h.	NULL
The	NULL
observation	NULL
that	NULL
macrophages	NULL
from	NULL
patients	NULL
with	NULL
CGD	NULL
,	NULL
which	NULL
are	NULL
unable	NULL
to	NULL
generate	NULL
important	NULL
amounts	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
,	NULL
were	NULL
as	NULL
sensitive	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
corticosteroids	NULL
as	NULL
were	NULL
normal	NULL
cells	NULL
,	NULL
points	NULL
to	NULL
killing	NULL
mechanisms	NULL
other	NULL
than	NULL
oxidative	NULL
systems	NULL
as	NULL
targets	NULL
for	NULL
the	NULL
corticosteroid	NULL
effect	NULL
.	NULL

From	NULL
the	NULL
studies	NULL
of	NULL
Werb	NULL
(	NULL
22	NULL
)	NULL
it	NULL
is	NULL
known	NULL
that	NULL
GC	NULL
concentrations	NULL
comparable	NULL
to	NULL
those	NULL
used	NULL
here	NULL
have	NULL
important	NULL
catabolic	NULL
effects	NULL
on	NULL
macrophages	NULL
such	NULL
as	NULL
reduction	NULL
of	NULL
the	NULL
synthesis	NULL
of	NULL
neutral	NULL
proteases	NULL
.	NULL

Since	NULL
most	NULL
,	NULL
if	NULL
not	NULL
all	NULL
,	NULL
receptor-mediated	NULL
GC	NULL
effects	NULL
are	NULL
related	NULL
to	NULL
a	NULL
modulation	NULL
of	NULL
protein	NULL
synthesis	NULL
(	NULL
28	NULL
)	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
corticosteroids	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
similarly	NULL
reflects	NULL
the	NULL
suppression	NULL
of	NULL
synthesis	NULL
of	NULL
proteins	NULL
of	NULL
the	NULL
antimicrobial	NULL
armature	NULL
of	NULL
the	NULL
phagocyte	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
time	NULL
lag	NULL
between	NULL
the	NULL
beginning	NULL
of	NULL
the	NULL
corticoid	NULL
exposure	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
killing	NULL
defect	NULL
could	NULL
indicate	NULL
that	NULL
such	NULL
suppressed	NULL
proteins	NULL
have	NULL
to	NULL
be	NULL
exhausted	NULL
to	NULL
a	NULL
critical	NULL
level	NULL
through	NULL
protein	NULL
turnover	NULL
.	NULL

Contrary	NULL
to	NULL
previous	NULL
observations	NULL
on	NULL
effects	NULL
of	NULL
excessive	NULL
concentrations	NULL
of	NULL
hydrocortisone	NULL
succinate	NULL
on	NULL
the	NULL
in	NULL
vitro	NULL
responsiveness	NULL
of	NULL
macrophages	NULL
to	NULL
lymphokines	NULL
(	NULL
16	NULL
)	NULL
,	NULL
dexamethasone	NULL
at	NULL
therapeutic	NULL
levels	NULL
did	NULL
not	NULL
affect	NULL
macrophage	NULL
activation	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
in	NULL
accord	NULL
with	NULL
the	NULL
recent	NULL
observation	NULL
of	NULL
Nash	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
that	NULL
cortisol	NULL
does	NULL
not	NULL
affect	NULL
Iymphokine-mediated	NULL
activation	NULL
of	NULL
human	NULL
macrophages	NULL
against	NULL
L.	NULL
pneumophila	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
on	NULL
Listeria	NULL
,	NULL
y-IFN	NULL
abolished	NULL
the	NULL
steroid	NULL
effect	NULL
within	NULL
a	NULL
few	NULL
hours	NULL
and	NULL
induced	NULL
an	NULL
antilisterial	NULL
activity	NULL
of	NULL
macrophages	NULL
exposed	NULL
to	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
dexamethasone	NULL
concentrations	NULL
which	NULL
was	NULL
superior	NULL
to	NULL
that	NULL
of	NULL
untreated	NULL
control	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
y-IFN	NULL
in	NULL
contrast	NULL
to	NULL
progesterone	NULL
appeared	NULL
to	NULL
override	NULL
and	NULL
not	NULL
to	NULL
antagonize	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
macrophages	NULL
,	NULL
possibly	NULL
by	NULL
affecting	NULL
other	NULL
killing	NULL
mechanisms	NULL
than	NULL
those	NULL
damaged	NULL
by	NULL
GC	NULL
.	NULL

This	NULL
concept	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
y-IFN	NULL
,	NULL
which	NULL
seems	NULL
to	NULL
enhance	NULL
oxidative	NULL
killing	NULL
(	NULL
26	NULL
)	NULL
,	NULL
had	NULL
in	NULL
contrast	NULL
to	NULL
experiments	NULL
with	NULL
Listeria	NULL
or	NULL
Salmonella	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
base-line	NULL
activity	NULL
of	NULL
macrophages	NULL
against	NULL
4s-pergillus	NULL
spores	NULL
,	NULL
which	NULL
apparently	NULL
are	NULL
not	NULL
killed	NULL
by	NULL
oxidative	NULL
mechanisms	NULL
(	NULL
18	NULL
)	NULL
.	NULL

y-IFN	NULL
similarly	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
complete	NULL
loss	NULL
of	NULL
the	NULL
bactericidal	NULL
activity	NULL
of	NULL
dexamethasone-treated	NULL
phagocytes	NULL
against	NULL
Nocardia	NULL
,	NULL
an	NULL
organism	NULL
which	NULL
,	NULL
like	NULL
Aspergillus	NULL
spores	NULL
but	NULL
unlike	NULL
Listeria	NULL
and	NULL
Salmonel/a	NULL
,	NULL
is	NULL
resistant	NULL
to	NULL
killing	NULL
by	NULL
neutrophil	NULL
granulocytes	NULL
(	NULL
7	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
observations	NULL
,	NULL
one	NULL
might	NULL
speculate	NULL
that	NULL
by	NULL
damaging	NULL
nonoxidative	NULL
killing	NULL
mechanisms	NULL
,	NULL
dexamethasone	NULL
affects	NULL
antimicrobial	NULL
activity	NULL
of	NULL
``	NULL
resting	NULL
``	NULL
macrophages	NULL
against	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
microorganisms	NULL
,	NULL
and	NULL
that	NULL
activation	NULL
of	NULL
oxidative	NULL
killing	NULL
systems	NULL
by	NULL
y-IFN	NULL
might	NULL
be	NULL
sufficient	NULL
for	NULL
some	NULL
but	NULL
not	NULL
all	NULL
microorganisms	NULL
to	NULL
correct	NULL
for	NULL
the	NULL
GC-damage	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
recent	NULL
observations	NULL
of	NULL
Mokoena	NULL
and	NULL
Gordon	NULL
(	NULL
31	NULL
)	NULL
,	NULL
which	NULL
indicate	NULL
that	NULL
dexamethasone	NULL
suppresses	NULL
lymphokine-induced	NULL
expression	NULL
of	NULL
several	NULL
markers	NULL
of	NULL
macrophage	NULL
activation	NULL
but	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
lymphokine-induced	NULL
enhancement	NULL
of	NULL
the	NULL
respiratory	NULL
burst	NULL
.	NULL

This	NULL
pathogen-dependent	NULL
dichotomy	NULL
in	NULL
the	NULL
opposing	NULL
effects	NULL
of	NULL
y-IFN	NULL
and	NULL
GC	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
might	NULL
explain	NULL
why	NULL
in	NULL
a	NULL
model	NULL
of	NULL
listeriosis	NULL
(	NULL
32	NULL
)	NULL
but	NULL
not	NULL
in	NULL
models	NULL
of	NULL
aspergillosis	NULL
(	NULL
7	NULL
)	NULL
,	NULL
mice	NULL
can	NULL
be	NULL
rendered	NULL
cortisone-resistant	NULL
by	NULL
prior	NULL
immunization	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
y-IFN	NULL
to	NULL
correct	NULL
for	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
GC	NULL
on	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
macrophages	NULL
against	NULL
some	NULL
microorganisms	NULL
hampers	NULL
somewhat	NULL
the	NULL
enthusiastic	NULL
outlook	NULL
(	NULL
21	NULL
)	NULL
for	NULL
the	NULL
possibility	NULL
of	NULL
multiple	NULL
simultaneous	NULL
immunomodulatory	NULL
interventions	NULL
such	NULL
as	NULL
an	NULL
im-munosuppression	NULL
with	NULL
corticosteroids	NULL
and	NULL
a	NULL
simultaneous	NULL
protection	NULL
from	NULL
opportunistic	NULL
infections	NULL
with	NULL
recombinant	NULL
y-IFN	NULL
.	NULL

Dexamethasone	NULL
added	NULL
to	NULL
cocultures	NULL
of	NULL
proliferating	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
did	NULL
not	NULL
prevent	NULL
activation	NULL
of	NULL
the	NULL
phagocyte	NULL
against	NULL
Listeria	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
this	NULL
in	NULL
vitro	NULL
model	NULL
which	NULL
depends	NULL
on	NULL
a	NULL
mitogen	NULL
or	NULL
on	NULL
a	NULL
recall	NULL
antigen	NULL
for	NULL
induction	NULL
of	NULL
lymphoproliferation	NULL
,	NULL
the	NULL
afferent	NULL
limb	NULL
of	NULL
cell-mediated	NULL
immunity	NULL
appeared	NULL
less	NULL
susceptible	NULL
to	NULL
therapeutic	NULL
GC	NULL
concentrations	NULL
than	NULL
the	NULL
effector	NULL
limb	NULL
,	NULL
the	NULL
macrophage	NULL
.	NULL

However	NULL
,	NULL
extrapolation	NULL
to	NULL
the	NULL
in	NULL
vivo	NULL
situation	NULL
is	NULL
hampered	NULL
by	NULL
other	NULL
effects	NULL
of	NULL
corticosteroids	NULL
on	NULL
cell-mediated	NULL
immunity	NULL
such	NULL
as	NULL
recruitment	NULL
of	NULL
lymphocytes	NULL
or	NULL
antigen	NULL
access	NULL
(	NULL
6	NULL
)	NULL
,	NULL
which	NULL
are	NULL
not	NULL
reflected	NULL
in	NULL
the	NULL
model	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
there	NULL
are	NULL
important	NULL
differences	NULL
between	NULL
a	NULL
secondary	NULL
and	NULL
a	NULL
primary	NULL
immune	NULL
response	NULL
that	NULL
can	NULL
not	NULL
be	NULL
studied	NULL
in	NULL
vitro	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
previous	NULL
comparison	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
cortisone	NULL
on	NULL
listeriosis	NULL
and	NULL
aspergillosis	NULL
in	NULL
genetically	NULL
athymic	NULL
and	NULL
normal	NULL
mice	NULL
suggests	NULL
that	NULL
the	NULL
macrophage	NULL
is	NULL
also	NULL
in	NULL
vivo	NULL
the	NULL
critical	NULL
target	NULL
for	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
in	NULL
these	NULL
infections	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Acknowledgments	NULL
I	NULL
wish	NULL
to	NULL
thank	NULL
Dr.	NULL
R.	NULL
Zinkernagel	NULL
for	NULL
the	NULL
EGD	NULL
strain	NULL
of	NULL
Listeria	NULL
mono-cytogenes	NULL
;	NULL
Dr.	NULL
G.	NULL
A.	NULL
Felice	NULL
for	NULL
the	NULL
GUH-2	NULL
strain	NULL
of	NULL
Nocardia	NULL
asteroides	NULL
,	NULL
and	NULL
Biogen	NULL
SA	NULL
,	NULL
Geneva	NULL
,	NULL
Switzerland	NULL
for	NULL
supplying	NULL
r-Interferon	NULL
gamma	NULL
.	NULL

I	NULL
also	NULL
thank	NULL
Dr.	NULL
R.	NULL
Keller	NULL
and	NULL
Dr.	NULL
T.	NULL
Schaffner	NULL
for	NULL
their	NULL
critical	NULL
and	NULL
encouraging	NULL
discussions	NULL
,	NULL
Eva	NULL
End	NULL
and	NULL
Ursula	NULL
Scharer	NULL
for	NULL
technical	NULL
as-sistance	NULL
,	NULL
and	NULL
R.	NULL
Shack	NULL
for	NULL
preparing	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
investigation	NULL
was	NULL
supported	NULL
by	NULL
grant	NULL
3.8	NULL
15.0.83	NULL
from	NULL
the	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
and	NULL
the	NULL
EMDO	NULL
Foundation	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Ginzler	NULL
,	NULL
E.	NULL
,	NULL
H.	NULL
Diamond	NULL
,	NULL
D.	NULL
Kaplan	NULL
,	NULL
M.	NULL
Weiner	NULL
,	NULL
M.	NULL
Schlesinger	NULL
,	NULL
and	NULL
M.	NULL
Seleznick	NULL
.	NULL

1978	NULL
.	NULL

Computer	NULL
analysis	NULL
of	NULL
factors	NULL
influencing	NULL
frequency	NULL
of	NULL
infection	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

21:37-44	NULL
.	NULL

2	NULL
.	NULL

Anderson	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
L.	NULL
A.	NULL
Schaffer	NULL
,	NULL
D.	NULL
B.	NULL
Olin	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Eickhoff	NULL
.	NULL

1973	NULL
.	NULL

Infectious	NULL
risk	NULL
factors	NULL
in	NULL
the	NULL
immunosuppressed	NULL
host	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

54:453-460	NULL
.	NULL

3	NULL
.	NULL

Gustafson	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
G.	NULL
B.	NULL
Lavely	NULL
,	NULL
C.	NULL
W.	NULL
Stratton	NULL
,	NULL
H.	NULL
K.	NULL
Johnson	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Hutcherson	NULL
,	NULL
Jr.	NULL
1983	NULL
.	NULL

Invasie	NULL
aspergillosis	NULL
in	NULL
renal	NULL
transplant	NULL
recipients	NULL
:	NULL
correlation	NULL
with	NULL
corticosteroid	NULL
therapy	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

148:230-238	NULL
.	NULL

4	NULL
.	NULL

Graham	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Tucker	NULL
.	NULL

1984	NULL
.	NULL

Opportunistic	NULL
infections	NULL
in	NULL
endogenous	NULL
Cushing	NULL
's	NULL
syndrome	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

101:334-338	NULL
.	NULL

5	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
K.	NULL
A.	NULL
Smith	NULL
,	NULL
and	NULL
A.	NULL
Munck	NULL
.	NULL

1979	NULL
.	NULL

Glucocorticoids	NULL
and	NULL
immune	NULL
responses	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

22:1246-1256	NULL
.	NULL

6	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
1979	NULL
.	NULL

Immunosuppressive	NULL
and	NULL
anti-inflammatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
.	NULL

In	NULL
Glucocorticoid	NULL
Hormone	NULL
Action	NULL
.	NULL

J.	NULL
D.	NULL
Baxter	NULL
and	NULL
G.	NULL
G.	NULL
Rousseau	NULL
,	NULL
editors	NULL
.	NULL

Springer	NULL
Publishing	NULL
Co.	NULL
,	NULL
Inc.	NULL
,	NULL
Berlin/Heidelberg/New	NULL
York	NULL
.	NULL

449-465	NULL
.	NULL

7	NULL
.	NULL

Schaffner	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Douglas	NULL
,	NULL
and	NULL
A.	NULL
Braude	NULL
.	NULL

1982	NULL
.	NULL

Selective	NULL
protection	NULL
against	NULL
conidia	NULL
by	NULL
mononuclear	NULL
and	NULL
against	NULL
mycelia	NULL
by	NULL
polymorpho-nuclear	NULL
phagocytes	NULL
in	NULL
resistance	NULL
to	NULL
Aspergillus	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

69:617-631	NULL
.	NULL

8	NULL
.	NULL

Schaffner	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Douglas	NULL
,	NULL
and	NULL
C.	NULL
E.	NULL
Davis	NULL
.	NULL

1983	NULL
.	NULL

Models	NULL
of	NULL
T	NULL
Glucocorticoid	NULL
Effect	NULL
on	NULL
Macrophages	NULL
|	NULL
1763	NULL
cell	NULL
deficiency	NULL
in	NULL
listeriosis	NULL
:	NULL
the	NULL
effects	NULL
of	NULL
cortisone	NULL
and	NULL
cyclosporin	NULL
A	NULL
on	NULL
normal	NULL
and	NULL
nude	NULL
BALB/c	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

131:450-453	NULL
.	NULL

9	NULL
.	NULL

Van	NULL
Zweit	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
J.	NULL
Thompson	NULL
,	NULL
and	NULL
R.	NULL
Van	NULL
Furth	NULL
.	NULL

1975	NULL
.	NULL

Effect	NULL
of	NULL
glucocorticosteroids	NULL
on	NULL
the	NULL
phagocytosis	NULL
and	NULL
intracellular	NULL
killing	NULL
by	NULL
peritoneal	NULL
macrophages	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

12:699-705	NULL
.	NULL

10	NULL
.	NULL

Nash	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
D.	NULL
M.	NULL
Libby	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Horwitz	NULL
.	NULL

1984	NULL
.	NULL

Interaction	NULL
between	NULL
Legionaires	NULL
'	NULL
disease	NULL
bacterium	NULL
(	NULL
Legionella	NULL
pneumophila	NULL
)	NULL
and	NULL
human	NULL
alveolar	NULL
macrophages	NULL
.	NULL

Influence	NULL
of	NULL
antibody	NULL
,	NULL
lymphokines	NULL
,	NULL
and	NULL
hydrocortisone	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:771-782	NULL
.	NULL

11	NULL
.	NULL

Rinehart	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
S.	NULL
P.	NULL
Balcerzak	NULL
,	NULL
A.	NULL
L.	NULL
Sagone	NULL
,	NULL
and	NULL
A.	NULL
F.	NULL
Lo	NULL
Buglio	NULL
.	NULL

1974	NULL
.	NULL

Effects	NULL
of	NULL
corticosteroids	NULL
on	NULL
human	NULL
monocyte	NULL
function	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

54:1337-1343	NULL
.	NULL

12	NULL
.	NULL

Peterson	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
S.	NULL
L.	NULL
Wyngaarden	NULL
,	NULL
S.	NULL
L.	NULL
Guerra	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Brodie	NULL
,	NULL
and	NULL
B	NULL
.	NULL

B.	NULL
Bunim	NULL
.	NULL

1955	NULL
.	NULL

The	NULL
physiologic	NULL
deposition	NULL
and	NULL
metabolic	NULL
rate	NULL
of	NULL
hydrocortisone	NULL
in	NULL
man	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

34:1779-1794	NULL
.	NULL

13	NULL
.	NULL

Webel	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
R.	NULL
E.	NULL
Ritts	NULL
,	NULL
Jr.	NULL
,	NULL
H.	NULL
F.	NULL
Taswell	NULL
,	NULL
J.	NULL
V.	NULL
Donadio	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Woods	NULL
.	NULL

1974	NULL
.	NULL

Cellular	NULL
immunity	NULL
after	NULL
intravenous	NULL
administration	NULL
of	NULL
methylprenisolone	NULL
.	NULL

J	NULL
.	NULL

Lab	NULL
.	NULL

Clin	NULL
.	NULL

Med	NULL
.	NULL

83:383-392	NULL
.	NULL

14	NULL
.	NULL

Ballard	NULL
,	NULL
P.	NULL
L.	NULL
1979	NULL
.	NULL

Delivery	NULL
and	NULL
transport	NULL
of	NULL
glucocorticoids	NULL
to	NULL
target	NULL
cells	NULL
.	NULL

In	NULL
Glucocorticoid	NULL
Hormone	NULL
Action	NULL
.	NULL

J.	NULL
D.	NULL
Baxter	NULL
and	NULL
G.	NULL
G.	NULL
Rousseau	NULL
,	NULL
editors	NULL
.	NULL

Springer	NULL
Publishing	NULL
Co.	NULL
,	NULL
Inc.	NULL
,	NULL
Berlin/Heidelberg/New	NULL
York	NULL
.	NULL

25-48	NULL
.	NULL

15	NULL
.	NULL

Blackwood	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Pennington	NULL
.	NULL

1982	NULL
.	NULL

Dose-dependent	NULL
effect	NULL
of	NULL
glucocorticosteroids	NULL
on	NULL
pulmonary	NULL
defense	NULL
in	NULL
a	NULL
steroid	NULL
resistant	NULL
host	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

126:1045-1049	NULL
.	NULL

16	NULL
.	NULL

Masur	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
W.	NULL
Murray	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Jones	NULL
.	NULL

1982	NULL
.	NULL

Effect	NULL
of	NULL
hydrocortisone	NULL
on	NULL
macrophage	NULL
response	NULL
to	NULL
lymphokine	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

35:1709-714	NULL
.	NULL

17	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
Leung	NULL
.	NULL

1977	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
and	NULL
mechanisms	NULL
of	NULL
action	NULL
.	NULL

/n	NULL
Receptors	NULL
and	NULL
Mechanism	NULL
of	NULL
Action	NULL
of	NULL
Steroid	NULL
Hormones	NULL
,	NULL
Part	NULL
II	NULL
.	NULL

Pasqualini	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
editor	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

18	NULL
.	NULL

Schaffner	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Douglas	NULL
,	NULL
A.	NULL
I.	NULL
Braude	NULL
,	NULL
and	NULL
C.	NULL
E.	NULL
Davis	NULL
.	NULL

1983	NULL
.	NULL

Killing	NULL
of	NULL
aspergillus	NULL
spores	NULL
depends	NULL
on	NULL
the	NULL
anatomical	NULL
souce	NULL
of	NULL
the	NULL
macrophage	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

2	NULL
:	NULL
1109-1115	NULL
.	NULL

19	NULL
.	NULL

Nagakawara	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
F.	NULL
Nathan	NULL
,	NULL
and	NULL
Z	NULL
.	NULL

A.	NULL
Cohn	NULL
.	NULL

1981	NULL
.	NULL

Hydrogen	NULL
peroxide	NULL
metabolism	NULL
in	NULL
human	NULL
monocytes	NULL
during	NULL
differentiation	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

68:1243-1252	NULL
.	NULL

20	NULL
.	NULL

Werb	NULL
,	NULL
Z.	NULL
,	NULL
R.	NULL
Foley	NULL
,	NULL
and	NULL
A.	NULL
Munck	NULL
.	NULL

1978	NULL
.	NULL

Interaction	NULL
of	NULL
gluco-	NULL
1764	NULL
-	NULL
A.	NULL
Schaffner	NULL
corticoids	NULL
with	NULL
macrophages	NULL
.	NULL

Identification	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
monocytes	NULL
and	NULL
macrophages	NULL
.	NULL

J.	NULL
Exp	NULL
:	NULL
Med	NULL
.	NULL

147:1684-1694	NULL
.	NULL

21	NULL
.	NULL

Reem	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
and	NULL
N.	NULL
H.	NULL
Yeh	NULL
.	NULL

1984	NULL
.	NULL

Interleukin	NULL
2	NULL
regulates	NULL
expression	NULL
of	NULL
its	NULL
receptor	NULL
and	NULL
synthesis	NULL
of	NULL
gamma	NULL
interferon	NULL
by	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

225:429-430	NULL
.	NULL

22	NULL
.	NULL

Werb	NULL
,	NULL
Z	NULL
.	NULL

1978	NULL
.	NULL

Biochemical	NULL
actions	NULL
of	NULL
glucocorticoids	NULL
on	NULL
macrophages	NULL
in	NULL
culture	NULL
.	NULL

Specific	NULL
inhibition	NULL
of	NULL
elastase	NULL
collagenase	NULL
,	NULL
and	NULL
plas-minogen	NULL
activator	NULL
secretion	NULL
and	NULL
effects	NULL
on	NULL
other	NULL
metabolic	NULL
functions	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

147:1695-1723	NULL
.	NULL

23	NULL
.	NULL

Ponec	NULL
,	NULL
M.	NULL
1982	NULL
.	NULL

Glucocorticoids	NULL
and	NULL
cultured	NULL
human	NULL
skin	NULL
cells	NULL
:	NULL
specific	NULL
intracellular	NULL
binding	NULL
and	NULL
structure-activity	NULL
relationship	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Dermatol	NULL
.	NULL

107	NULL
(	NULL
Suppl	NULL
.	NULL

23	NULL
)	NULL
:24-29	NULL
.	NULL

24	NULL
.	NULL

Celada	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
W.	NULL
Gray	NULL
,	NULL
E.	NULL
Rinderknecht	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Schreiber	NULL
.	NULL

1984	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
gamma-interferon	NULL
receptor	NULL
that	NULL
regulates	NULL
macrophage	NULL
tumoricidal	NULL
activity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

160:55-74	NULL
.	NULL

25	NULL
.	NULL

Schultz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Kleinschmidt	NULL
.	NULL

1983	NULL
.	NULL

Functional	NULL
identity	NULL
between	NULL
murine	NULL
gamma-interferon	NULL
and	NULL
macrophage	NULL
activating	NULL
factor	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

305:239-240	NULL
.	NULL

26	NULL
.	NULL

Nathan	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
H.	NULL
W.	NULL
Murray	NULL
,	NULL
M.	NULL
E.	NULL
Weibe	NULL
,	NULL
and	NULL
B.	NULL
Y.	NULL
Rubin	NULL
.	NULL

1983	NULL
.	NULL

Identification	NULL
of	NULL
interferon-gamma	NULL
as	NULL
the	NULL
lymphokine	NULL
that	NULL
activates	NULL
human	NULL
macrophage	NULL
oxidative	NULL
metabolism	NULL
and	NULL
antimicrobial	NULL
activity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

158:670-689	NULL
.	NULL

27	NULL
.	NULL

Baumann	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Rappaport	NULL
,	NULL
T.	NULL
Lemarchand-Beraud	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Felber	NULL
.	NULL

1975	NULL
.	NULL

Free	NULL
cortisol	NULL
index	NULL
:	NULL
a	NULL
rapid	NULL
and	NULL
simple	NULL
estimation	NULL
of	NULL
free	NULL
cortisol	NULL
in	NULL
human	NULL
plasma	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

40:462-469	NULL
.	NULL

28	NULL
.	NULL

O'Malley	NULL
,	NULL
B.	NULL
W.	NULL
1984	NULL
.	NULL

Steroid	NULL
hormone	NULL
action	NULL
in	NULL
eucaryotic	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:307-312	NULL
.	NULL

29	NULL
.	NULL

Rinehart	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
A.	NULL
L.	NULL
Sagone	NULL
,	NULL
S.	NULL
P.	NULL
Balcerzak	NULL
,	NULL
G.	NULL
A.	NULL
Ackermann	NULL
,	NULL
and	NULL
A.	NULL
F.	NULL
LoBuglio	NULL
.	NULL

1975	NULL
.	NULL

Effects	NULL
of	NULL
corticosteroid	NULL
therapy	NULL
on	NULL
human	NULL
monocyte	NULL
function	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

292:236-241	NULL
.	NULL

30	NULL
.	NULL

Felice	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
B.	NULL
L.	NULL
Beaman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Krick	NULL
,	NULL
and	NULL
J.	NULL
Remington	NULL
.	NULL

1980	NULL
.	NULL

Effects	NULL
of	NULL
human	NULL
neutrophils	NULL
and	NULL
monocytes	NULL
on	NULL
Nocardia	NULL
asteroides	NULL
:	NULL
failure	NULL
of	NULL
killing	NULL
despite	NULL
occurrence	NULL
of	NULL
the	NULL
oxidative	NULL
metabolic	NULL
burst	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

142:432-438	NULL
.	NULL

31	NULL
.	NULL

Mokoena	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
S.	NULL
Gordon	NULL
.	NULL

1985	NULL
.	NULL

Human	NULL
macrophage	NULL
activation	NULL
.	NULL

Modulation	NULL
of	NULL
mannosyl	NULL
,	NULL
fucosyl	NULL
receptor	NULL
activity	NULL
in	NULL
vitro	NULL
by	NULL
lymphokines	NULL
,	NULL
gamma	NULL
and	NULL
alpha	NULL
interferons	NULL
,	NULL
and	NULL
dexamethasone	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

75:624-631	NULL
.	NULL

32	NULL
.	NULL

North	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

1971	NULL
.	NULL

The	NULL
action	NULL
of	NULL
cortisone	NULL
acetate	NULL
on	NULL
cell-mediated	NULL
immunity	NULL
to	NULL
infection	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

134:1485-1500	NULL
.	NULL

